Context-dependent cytokine effects in epilepsy: cellular source, anatomical compartment, and epileptogenesis stage, not concentration alone
概念框架:细胞因子效应的来源依赖性、空间分区与疾病阶段决定论
整合三份分组中所有总论性、综述性文献,共同论证同一炎症介质(IL-1、TNF-α、IL-6、IL-2、NLRP3炎症小体、IL-12家族、HMGB1等危险信号)的神经调控结局不由浓度单独决定,而取决于产生细胞、局部受体环境、空间定位(脑实质、血管周围间隙、脑膜)与致痫进程阶段;为全文所有细胞来源分述提供统一理论支点,是综述的总纲而非某一细胞专题。
- The NLRP3 inflammasome as a dynamic context-dependent regulator: mechanisms, disease progression, and therapeutic implications(Shuo Liu, Xun Liu, Jing Hu, He Chen, Si-Wen Yang, Juan Feng, Yi Sui, 2026, Journal of Translational Medicine)
- The IL 12 Cytokine Family in Cardiovascular Disease: Context Dependent Signaling, Immune Remodeling, and Therapeutic Implications(Xing Meng, Chao Wang, 2026, Immunological Investigations)
- Neuroinflammation microenvironment sharpens seizure circuit.(B. Villasana-Salazar, A. Vezzani, 2023, Neurobiology of Disease)
- Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits(C. Whyte, Kailash Singh, O. Burton, M. Aloulou, Lubna Kouser, R. Veiga, Amy Dashwood, H. Okkenhaug, S. Benadda, Alena Moudra, Orian Bricard, Stephanie Lienart, P. Bielefeld, C. Roca, Francisco Jose Naranjo-Galindo, Félix Lombard-Vadnais, S. Junius, D. Bending, Masahiro Ono, T. Hochepied, T. Halim, Susan M. Schlenner, S. Lesage, J. Dooley, A. Liston, 2020, bioRxiv)
- 2.4 The inflammatory molecules IL-1β and HMGB1 can rap- idly enhance focal seizure generation in rat entorhinal cor- tex(A. Chiavegato, G. Losi, E. Aronica, G. Carmignoto, 2013, No journal)
- Neuroinflammation in the Genesis of Epilepsy(Rashmi Rani, S. Paliwal, S. Nain, 2025, Current Psychopharmacology)
- The spatial architecture of neuroimmune interactions in epilepsy(D. Chu, Wu-Hao Zhang, Xing Zhou, Hang Yin, Jian Yin, 2026, Frontiers in Immunology)
- Modulation of neuronal excitability by immune mediators in epilepsy(V. Iori, F. Frigerio, A. Vezzani, 2015, Current opinion in pharmacology (Print))
- [Cytokines and the nervous system: the relationship between seizures and epilepsy].(S. F. Velasco-Ramírez, L. Y. Rosales-Rivera, A. C. Ramírez-Anguiano, O. Bitzer-Quintero, 2013, Revista de neurología (Ed. impresa))
- Role of Glial Cells in Seizures and Epilepsy: Intracellular Calcium Oscillations and Spatial Buffering(F. Dudek, 2002, Epilepsy Currents)
小胶质细胞:癫痫后最早应答者、TNF-α/IL-1β/IL-6主要来源与促痫-保护双重面貌
合并三份分组中聚焦小胶质细胞本体功能的文献:一方面以Kv1.3阻断、槲皮素抑制NF-κB、抗TNF-α/抗IL-1β单抗、ATP-腺苷负反馈、MCT4缺失等证据表明其早期活化与细胞因子释放增强谷氨酸能传递、削弱GABA能抑制并加重发作;另一方面通过突触修剪、吞噬与组织修复、密度-活化平衡及综述性"双面性"论述,证明同一细胞在不同情境下可保护神经元,直接支撑效应方向随语境反转的论点。
- Blockade of Kv1.3 Potassium Channel Inhibits Microglia-Mediated Neuroinflammation in Epilepsy(Xin-Yi Zhang, Peiyu Liang, Yahui Zhang, Yi-Fan Wu, Yinghao Song, Xue-Yang Wang, Tao-Xiang Chen, B. Peng, Wan-Hong Liu, Jun Yin, Song Han, Xiao-Hua He, 2022, International Journal of Molecular Sciences)
- Ameliorating effect of quercetin on epilepsy by inhibition of inflammation in glial cells(Dong-Mei Wu, Zi-Hui Zheng, Shao-Hua Fan, Xin Wen, Xin-Rui Han, Shan Wang, Yong-Jian Wang, Zi-Feng Zhang, Qun Shan, Mengqiu Li, Bin Hu, Yuan-Lin Zheng, Jun Lu, 2020, Experimental and Therapeutic Medicine)
- Anti-TNFα and Anti-IL-1β Monoclonal Antibodies Preserve BV-2 Microglial Homeostasis Under Hypoxia by Mitigating Inflammatory Reactivity and ATF4/MAPK-Mediated Apoptosis(Linglin Zhang, Chaoqiang Guan, Sudena Wang, Norbert Pfeiffer, F. Grus, 2025, Antioxidants)
- Contribution of microglia to the epileptiform activity that results from neonatal hypoxia.(A. Leavy, J. Phelan, E. Jimenez-Mateos, 2024, Neuropharmacology)
- Balancing Microglial Density and Activation in Central Nervous System Development and Disease(Shun-Qi Wang, Liangjing Pan, Chong Sun, Chao-Lin Ma, Hai-Li Pan, 2025, Current Issues in Molecular Biology)
- The Double Face of Microglia in the Brain(Moisés Rubio-Osornio, C. Rubio, M. Ganado, Héctor Romo-Parra, 2026, Neuroglia)
- The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS(C. Arcuri, C. Mecca, R. Bianchi, I. Giambanco, R. Donato, 2017, Frontiers in Molecular Neuroscience)
- Synaptic Pruning by Microglia in Epilepsy(Megumi Andoh, Y. Ikegaya, Ryuta Koyama, 2019, Journal of Clinical Medicine)
- Reactive microglia fail to respond to environmental damage signals in a viral-induced mouse model of temporal lobe epilepsy(Glenna J. Wallis, Laura A. Bell, Jan Wagner, Lauren Buxton, Lakshmini Balachandar, Karen S. Wilcox, 2024, bioRxiv)
- Repeated seizure-induced brainstem neuroinflammation contributes to post-ictal ventilatory control dysfunction(Wasif A. Osmani, Alexander Gallo, Madeline Tabor, Melissa A. Eilbes, Denise R. Cook-Snyder, Matthew R. Hodges, 2024, Frontiers in Physiology)
- Negative feedback control of neuronal activity by microglia(Ana Badimon, Hayley J. Strasburger, Pinar Ayata, Xinhong Chen, Aditya Nair, Ako Ikegami, Philip Hwang, Andrew T. Chan, Steven M. Graves, Joseph O. Uweru, Carola Ledderose, M. G. Kutlu, Michael A. Wheeler, A. Kahan, Masago Ishikawa, Ying-Chih Wang, Y. Loh, J. Jiang, D. Surmeier, S. Robson, W. Junger, R. Sebra, Erin S. Calipari, P. Kenny, Ukpong B. Eyo, M. Colonna, F. Quintana, H. Wake, V. Gradinaru, A. Schaefer, 2020, Nature)
- Loss of microglial MCT4 leads to defective synaptic pruning and anxiety-like behavior in mice(Katia Monsorno, K. Ginggen, Andranik Ivanov, An Buckinx, Arnaud L. Lalive, Anna Tchenio, Sam Benson, M. Vendrell, A. D'Alessandro, D. Beule, Luc Pellerin, M. Mameli, R. Paolicelli, 2023, Nature Communications)
- The role of microglia in radiation-induced changes in the brain: from neuroprotection to neuroinflammation. Review(S. S. Sorokina, D. Gromova, O. Belov, N. R. Popova, 2026, Radiation and Risk Bulletin of the National Radiation and Epidemiological Registry)
- Microglial Plasticity in Vascular Dementia: Mechanisms and Therapeutic Reprogramming(Manish Shukla, Jarvis Li, Yan Sun, Rong Jin, Guo-Hong Li, 2026, International Journal of Molecular Sciences)
小胶质细胞补体依赖的病理性突触修剪:E/I失衡、惊厥阈值与可挽救性
保留为独立板块:这组文献专门讨论补体C1q/C3标记、ATM与吞噬体介导的过度修剪,优先清除抑制性突触、破坏兴奋/抑制平衡并降低惊厥阈值,同时证明恢复ATM或靶向补体-小胶质轴可挽救突触完整性与认知功能。其机制主线(吞噬而非细胞因子分泌)与上一板块不同,合并会使主题笼统化。
- Microglial pathological synaptic pruning in epilepsy: pathophysiology and therapeutic potential(Yu-Lei Sun, Dong-Lan Zhou, Jiayi Li, Haonan Wu, Jianmin Liang, Bo Zhang, 2026, Frontiers in Immunology)
- Loss of microglial ATM drives synaptic pruning and cognitive impairment in epilepsy.(Yang Hu, Jin-Yu Zhao, Youli Wang, Mingjuan Tan, Lei Wang, Honggang Qi, Jiurong Yang, Xinjian Zhu, 2026, Free Radical Biology & Medicine)
- Targeting the Complement–Microglia Axis for Neuroprotection in Pediatric Epilepsy(Marah Karayanni, Nikolaos Mitsoudis, Maria Vanakliotou, Christos Bakirtzis, Evangelia Kesidou, Eleni Polyzoidou, E. Liana, 2026, Biomedicines)
星形胶质细胞:谷氨酸摄取与钾缓冲失调放大超兴奋,反应性极化与胶质瘢痕的双向效应
合并三份分组中全部星形胶质细胞文献为单一但具体的板块:GLT-1/GLAST/EAAT2谷氨酸清除(含ADGRV1调控、NEO1缺失、神经元囊泡miR-181c-5p经PKCδ下调GLT-1、IL-1β调控转运体)、GS与Gln-Glu代谢动力学模型、mGluR5条件性敲除、Kir4.1/Kir2.1钾空间缓冲与AQP4/内足脱离、以及A1型极化、GFAP上调、胶质瘢痕电生理与星形胶质MAGL缺失经CB1-PPARγ抑制促炎转化的保护性表型,共同说明同一细胞类型既放大网络兴奋又可限制炎症与神经元损伤。
- Astrocyte Glutamate Uptake and Signaling as Novel Targets for Antiepileptogenic Therapy(Allison R. Peterson, D. Binder, 2020, Frontiers in Neurology)
- Hippocampal astrocytic neogenin regulating glutamate uptake, a critical pathway for preventing epileptic response(Dong Sun, Zhi-Bing Tan, Xiang-Dong Sun, Zhi-Peng Liu, Wen-Bing Chen, Leena Milibari, Xiao Ren, Ling‐ling Yao, Daehoon Lee, Cheng-Yong Shen, Jin-Xiu Pan, Zhihui Huang, L. Mei, Wen-Cheng Xiong, 2021, Proceedings of the National Academy of Sciences of the United States of America)
- Neuronal small extracellular vesicles carrying miR‐181c‐5p contribute to the pathogenesis of epilepsy by regulating the protein kinase C‐δ/glutamate transporter‐1 axis in astrocytes(Limin Ma, Qingyuan Wu, Yu You, Peng Zhang, Dan-Dan Tan, Minxue Liang, Yun-Yi Huang, Yuan Gao, Yuenan Ban, Yang-Mei Chen, Jinxian Yuan, 2024, Glia)
- Astrocyte dysregulation as an epileptogenic factor: a systematic review(K. Sumadewi, B. D. de Liyis, N. M. Linawati, I. Widyadharma, I. Astawa, 2024, The Egyptian Journal of Neurology Psychiatry and Neurosurgery)
- Region-Specific Astrocyte Endfeet Disruption as a Driver of Pyramidal Neuron Death after Ischemia-Reperfusion in the Hippocampus(Joongbum Moon, J. Ahn, Moo-Ho Won, 2025, Biocell (Mendoza))
- Downregulation of Kir4.1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes(Yuriy V. Kucheryavykh, L. Kucheryavykh, C. Nichols, H. Maldonado, K. Baksi, A. Reichenbach, S. Skatchkov, M. Eaton, 2007, Glia)
- Interaction Between Glial Cells and Cerebellar Circuits in Epilepsy(Javier Pérez-Villavicencio, Ricardo Pérez-Rubio Flores, Héctor Romo-Parra, C. Rubio, 2026, Neuroglia)
- Adaptive Gene Expression Induced by a Combination of IL-1β and LPS in Primary Cultures of Mouse Astrocytes(Thierry Coppola, Gwénola Poupon, Hélène Rangone, S. Martin, Patricia Lebrun, 2025, Cells)
- Inhibition of endocannabinoid degradation in astrocytes reprograms glial reactivity and prevents seizure sequelae(Chudai Zeng, Fei Gao, Mei Hu, Jian Zhang, De-Xiao Zhu, Li Sun, Jianlu Lyu, Mingzhe Pan, Chu Chen, 2026, bioRxiv)
- The adhesion GPCR ADGRV1 controls glutamate homeostasis in hippocampal astrocytes supporting neuron development: first insights into to pathophysiology of ADGRV1-associated epilepsy(B. Guler, Mark Zorin, Joshua Linnert, Kerstin Nagel-Wolfrum, U. Wolfrum, 2024, bioRxiv)
- Astrocyte membrane properties are altered in a rat model of developmental cortical malformation but single-cell astrocytic glutamate uptake is robust(Elizabeth Hanson, N. C. Danbolt, C. Dulla, 2016, Neurobiology of Disease)
- Inflammatory cytokine, IL-1β, regulates glial glutamate transporter via microRNA-181a in vitro.(Joannee Zumkehr, C. J. Rodriguez-Ortiz, Rodrigo Medeiros, M. Kitazawa, 2018, Journal of Alzheimer's Disease)
- Potassium and glutamate transport is impaired in scar-forming tumor-associated astrocytes(S. C. Campbell, Carmen Muñoz-Ballester, Lata Chaunsali, William A. Mills, Jennifer H. Yang, H. Sontheimer, S. Robel, 2019, Neurochemistry International)
- Conditional Knock-out of mGluR5 from Astrocytes during Epilepsy Development Impairs High-Frequency Glutamate Uptake(Anthony D. Umpierre, P. West, John A. White, K. Wilcox, 2018, Journal of Neuroscience)
- Focal astrocyte Kir4.1 loss drives seizures, spreading depolarizations and postictal impairments(N. Codadu, Yunan Gao, O. Tyurikova, Zixi Dai, Xueting Ban, Yu-Yan Weng, E. Masvidal-Codina, J. A. Garrido, A. Guimerà-Brunet, D. Rusakov, Kevan S. Hashemi, N. Mazarakis, Rob C. Wykes, 2026, bioRxiv)
- Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer's disease(Hattapark Dejakaisaya, P. Kwan, N. Jones, 2021, Epilepsia)
- Dynamical modeling and analysis of epileptic discharges transition caused by glutamate release with metabolism processes regulation from astrocyte.(Duo Li, Qiang Li, Rui Zhang, 2024, Chaos)
- Astrocytic modulation of potassium under seizures(Fu-Shun Wang, Xiaoming Qi, Jun Zhang, Jason H. Huang, 2019, Neural Regeneration Research)
- Conditional Knock-Out of Kir4.1 Leads to Glial Membrane Depolarization, Inhibition of Potassium and Glutamate Uptake, and Enhanced Short-Term Synaptic Potentiation(Biljana Djukic, Kristen B. Casper, Benjamin D. Philpot, L. Chin, K. Mccarthy, 2007, Journal of Neuroscience)
- Oxidative stress targets Kir2.1 channel in a model of aging neuroglia(Alessia Remigante, R. Morabito, S. Spinelli, A. Marino, A. Sarikas, M. Pusch, S. Dossena, 2022, The FASEB Journal)
- Electrophysiological characteristics of reactive astrocytes in experimental cortical dysplasia.(A. Bordey, S. A. Lyons, J. J. Hablitz, Harald Sontheimer, 2001, Journal of Neurophysiology)
- Silencing of miR‐132‐3p protects against neuronal injury following status epilepticus by inhibiting IL‐1β‐induced reactive astrocyte (A1) polarization(Wen Zhang, Fang-Hua Ye, J. Xiong, F. He, L. Yang, F. Yin, Jing Peng, Xiaole Wang, 2022, The FASEB Journal)
- The Flavonoid Agathisflavone Attenuates Glia Activation After Mechanical Injury of Cortical Tissue and Negatively Regulates Both NRLP3 and IL-1β Expression(Verônica Moreira de Sousa, Á. M. Almeida, R. S. Ferreira, B. L. Dos Santos, Victor Diogenes Amara da Silva, J. M. David, C. D. dos Santos, S. L. Costa, 2025, International Journal of Molecular Sciences)
- Astroglial Scarring and Seizures(S. Robel, 2017, The Neuroscientist)
多胶质细胞协同驱动抑制性网络重塑与致痫性可塑性
保留其独特性:这组文献把星形胶质GABA/谷氨酰胺供给、小胶质炎症信号与少突胶质髓鞘重塑整合为"多胶质抑制性可塑性"模型,论证胶质细胞可主动驱动癫痫发生而非仅被动反应,为"同一介质效应取决于贡献它的细胞组合"提供跨细胞类型证据,无法归入单一细胞专题。
- Glia as drivers of abnormal neuronal activity(S. Robel, H. Sontheimer, 2015, Nature Neuroscience)
- Multi-glial inhibitory plasticity in epilepsy and sleep: implications for post-traumatic epileptogenesis.(P. K. Saha, Rachel K. Rowe, Detlev Boison, Oleksii Shandra, 2026, Experimental Neurology)
- Role of Glial Cells in Seizures and Epilepsy: Intracellular Calcium Oscillations and Spatial Buffering(F. Dudek, 2002, Epilepsy Currents)
神经元源性危险信号(HMGB1、miR-124等DAMPs)经TLR4/RAGE启动并传播炎症级联
合并三份分组中的HMGB1模块:证明炎症并非仅由胶质发起——过度兴奋或损伤的神经元使HMGB1核转位并释放至树突与细胞外空间,经TLR4/RAGE-NF-κB激活胶质并招募T细胞,热性惊厥持续状态模型中HMGB1转位与miR-124外释呈现快速时间动态,miR129-5p外泌体、甘草酸及miR-340-5p/IRF1/USP18轴等可干预,并含IL-1β/IL-6/HMGB1基因变异与发作后血清水平关联,支持神经元作为炎症起点兼有个体差异。
- Role of Innate Immune Receptor TLR4 and its endogenous ligands in epileptogenesis.(Y. Paudel, Efthalia Angelopoulou, E. Akyuz, C. Piperi, Iekhsan Othman, Mohd. Farooq Shaikh, 2020, Pharmacological Research)
- Multiple Disruptions of Glial-Neuronal Networks in Epileptogenesis That Follows Prolonged Febrile Seizures(G. Brennan, Megan M Garcia-Curran, Katelin P. Patterson, Renhao Luo, T. Baram, 2021, Frontiers in Neurology)
- Association Analysis of Interleukin-1β, Interleukin-6, and HMGB1 Variants with Postictal Serum Cytokine Levels in Children with Febrile Seizure and Generalized Epilepsy with Febrile Seizure Plus(Jieun Choi, S. Choi, S. Kim, H. Kim, B. Lim, H. Hwang, Hee-Chae Jong, Ki Joong Kim, Sohee Oh, E. Kim, Jeon-Soo Shin, 2019, Journal of Clinical Neurology)
- Time courses of HMGB1 and other inflammatory markers after generalized convulsive seizures.(R. D. Nass, M. Wagner, R. Surges, S. Holdenrieder, 2020, Epilepsy Research)
- Extracellular HMGB1 Released by NMDA Treatment Confers Neuronal Apoptosis via RAGE-p38 MAPK/ERK Signaling Pathway(Seung‐Woo Kim, Chae-Moon Lim, Jung-Bin Kim, Joo-Hyun Shin, Sang-Hoon Lee, Minhyung Lee, Ja-Kyeong Lee, 2011, Neurotoxicity research)
- Glycyrrhizin Suppresses HMGB1 Inductions in the Hippocampus and Subsequent Accumulation in Serum of a Kainic Acid-Induced Seizure Mouse Model(Li-Dan Luo, Yinchuan Jin, Il-Doo Kim, Ja-Kyeong Lee, 2014, Cellular and molecular neurobiology)
- HMGB1 mediates microglia activation via the TLR4/NF-κB pathway in coriaria lactone induced epilepsy(Yun-bo Shi, Lingli Zhang, J. Teng, Wang Miao, 2018, Molecular Medicine Reports)
- MiR129-5p-loaded exosomes suppress seizure-associated neurodegeneration in status epilepticus model mice by inhibiting HMGB1/TLR4-mediated neuroinflammation(Tengfei Liu, Haiyan Liu, Si-Yi Xue, Li-Jie Xiao, Jing Xu, Shu-Yan Tong, Xiu'e Wei, 2024, Molecular Biology Reports)
- Abstract 145: High Mobility Group Box 1 (HMGB1) is a Major Mediator of the Post-cardiac Arrest Syndrome(Emilie Boissady, Cynthia El Hedjaj, M. Kohlhauer, F. Lidouren, B. Ghaleh, R. Tissier, 2020, Circulation)
- Role of the miR-340-5p/IRF1/USP18 Axis in Neuroinflammation Associated with Epilepsy(Jing Liu, Yi-Ting Wang, Bibi Yazgulyyeva, Dan-Dan Sheng, Xinru Li, Luo Zhou, Bo Xiao, Weiping Liu, 2026, Neurochemical Research)
血脑屏障破坏与外周髓系细胞、单核/巨噬细胞及T细胞浸润:解剖界面与受体谱、时相差异
合并三份分组中的BBB与浸润模块:白蛋白外渗经TGF-β驱动星形胶质功能障碍与钾缓冲受损、CD8 T细胞经MHC I限制性机制参与BBB破坏、BBB内皮固有免疫感受器与脑膜淋巴引流、小胶质细胞较浸润髓系细胞促炎性更低、炎性单核细胞与小胶质细胞功能独立、髓系EP2活化、LPS外周炎症与雷帕霉素干预等,系统论证外周免疫细胞在受体谱、细胞因子谱与时间动态上与驻留胶质不同,构成独立的"外周-中枢界面"证据层。
- The Role of Blood–Brain Barrier Disruption in Epilepsy: Mechanisms and Consequences(E. Suleymanova, A. Karan, 2025, Neurology International)
- CD8 T cells as drivers of blood–brain barrier disruption(Marina Seady, Aaron J. Johnson, 2025, Trends in Neurosciences)
- Myeloid EP2 Receptors in Status Epilepticus—Peripheral But Not Negligible(Christina Gross, 2021, Epilepsy Currents)
- Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus(Ying-Hao Ho, Yu-Te Lin, Chih-Wei J. Wu, Y. Chao, A. Y. Chang, J. Chan, 2015, Journal of Biomedical Sciences)
- Rapamycin Plays an Anti-Epileptic Role by Restoring Blood-Brain Barrier Dysfunction, Balancing T Cell Subsets and Inhibiting Neuronal Apoptosis.(Pu-Song Xie, Shao-Bo Zhu, Huo-Wang Zhou, Runtao Fang, Jin-Ling Zhuang, Jie Wen, Miao-Xiong Yang, Jinshui He, 2023, Discover medicine)
- Inflammation caused by peripheral immune cells across into injured mouse blood brain barrier can worsen postoperative cognitive dysfunction induced by isoflurane(Honghua Zhu, Wei Liu, Hao Fang, 2018, BMC Cell Biology)
- Links between Immune Cells from the Periphery and the Brain in the Pathogenesis of Epilepsy: A Narrative Review(G. Yamanaka, Shinichiro Morichi, Tomoko Takamatsu, Yusuke Watanabe, Shinji Suzuki, Yu Ishida, S. Oana, Takashi Yamazaki, F. Takata, H. Kawashima, 2021, International Journal of Molecular Sciences)
- Low CSF CD4/CD8+ T-cell proportions are associated with blood-CSF barrier dysfunction in limbic encephalitis.(Niels Hansen, Kerstin Schwing, Demet Önder, G. Widman, Pitshaporn Leelaarporn, Indra Prusseit, R. Surges, N. Melzer, C. Gross, A. Becker, J. Witt, C. Elger, C. Helmstaedter, 2019, Epilepsy & Behavior)
- Some cross-talks between immune cells and epilepsy should not be forgotten(Hong Wang, Sibo Liu, Ze-Yao Tang, Jin-Jie Liu, 2014, Neurological Sciences)
- The blood-brain barrier-gatekeeper to neuronal homeostasis: clinical implications in the setting of stroke.(Karl Schoknecht, Yaron David, U. Heinemann, 2015, Seminars in Cell and Developmental Biology)
- Innate immune sensors and regulators at the blood brain barrier: focus on toll-like receptors and inflammasomes as mediators of neuro-immune crosstalk and inflammation(Cigdem Acioglu, Stella Elkabes, 2025, Journal of Neuroinflammation)
- Microglia are less pro‐inflammatory than myeloid infiltrates in the hippocampus of mice exposed to status epilepticus(J. Vinet, Ilia D. Vainchtein, C. Spano, Carmela Giordano, D. Bordini, Giulia Curia, M. Dominici, H. Boddeke, Bart J. L. Eggen, G. Biagini, 2016, Glia)
- Inflammatory monocytes and microglia play independent roles in inflammatory ictogenesis(C. Howe, Reghann Lafrance-Corey, Brittany L. Overlee, Renee K. Johnson, B. Clarkson, E. Goddery, 2022, Journal of Neuroinflammation)
- Peripheral blood mononuclear cell activation sustains seizure activity(L. Librizzi, Diogo Vila Verde, F. Colciaghi, F. Deleo, M. C. Regondi, Massimo Costanza, B. Cipelletti, M. Curtis, 2021, Epilepsia)
- Glymphatic-meningeal lymphatic dysfunction in epilepsy: Novel mechanistic insights and therapeutic avenues.(Yuan-Teng Fan, Meng-chao Liu, Tao-Xiang Chen, Bi-Wen Peng, 2026, Pharmacology and Therapeutics)
外周细胞因子、趋化因子与补体谱的时空表达及其与癫痫临床表型的关联
合并三份分组中的临床/生物标志物模块:癫痫后CCL2/CCL3/CCL5/IL-1β在不同脑区与时间点的差异表达、药物难治性癫痫患者血清补体的性别特异性改变、儿童耐药性癫痫中IL-1β与GDNF水平同严重度的关系、神经精神共病与发作相关指标,以及外周血单个核细胞活化状态,说明外周免疫谱可作为分型与疗效预测指标,体现"解剖分区与疾病阶段"对介质效应的调制。
- Increased CCL2, CCL3, CCL5, and IL-1β cytokine concentration in piriform cortex, hippocampus, and neocortex after pilocarpine-induced seizures(G. M. Arisi, M. Foresti, K. Katki, Lee A. Shapiro, 2015, Journal of Neuroinflammation)
- Sex-Specific Complement and Cytokine Imbalances in Drug-Resistant Epilepsy: Biomarkers of Immune Vulnerability(Nicole Pinzón-Hoyos, Yi-Bo Li, Monnie McGee, N. P. Poolos, Nicola Marchi, Amy L. Brewster, 2024, bioRxiv)
- Neuropsychiatric symptoms and seizure related with serum cytokine in epilepsy patients(Hye-Rim Shin, K. Chu, Woo-Jin Lee, Han Lee, Eun Young Kim, Hyoshin Son, J. Moon, Na-Yul Kim, K. Jung, Keun-Hwa Jung, Soon-Tae Lee, Kyung-Il Park, S. Lee, 2022, Scientific Reports)
- Drug-resistant epilepsy associated with peripheral complement decreases and sex-specific cytokine imbalances: a pilot study(Nicole Pinzón-Hoyos, Yi-Bo Li, Monnie McGee, N. P. Poolos, Nicola Marchi, Amy L. Brewster, 2025, Scientific Reports)
- Neuroprotective and inflammatory biomarkers in pediatric drug-resistant epilepsy: Interplay between GDNF, IL-1β and vitamin D 25-OH(Johannes H. Saing, D. Sari, Supriatmo Supriatmo, Aida Fithrie, M. Rusda, M. Amin, Muhammad A. Pratama, 2024, Narra J)
- [Targeting diagnosis and treatment value of chelating anti-IL-1β mAb-SPIONs in temporal lobe epilepsy model].(Y.-L. Wang, X.-B. Hu, L.-Y. Gao, Xi-Ru Wu, X. Chu, S.-H. Zhou, Qing-Xia Kong, 2018, Zhonghua yi xue za zhi)
情境选择性的抗炎与免疫调节干预:从单抗靶向递送、TLR配体预处理到植物提取物与神经调控
将三份分组中散落的治疗学文献整合为独立板块,回应"不同细胞来源受体表达与信号阈值不同、对抗炎治疗反应各异"的论点:包括IL-1β单抗的靶向递送价值评估、单磷酰脂质A/Pam3Cys预处理、拉莫三嗪、曲美他嗪、三七花提取物、formononetin、VNS对细胞因子的调节、小胶质-星形胶质IL-3/IL-3R串扰等,说明需按细胞来源、受体环境与疾病阶段分层设计干预,而非采用统一抗炎策略。
- Panax notoginseng Flower Extract Attenuates Pentylenetetrazole-Induced Epilepsy by Restoring Glutamate Homeostasis(Yang Zhao, Feiya Zhu, Jiayu Xie, Yiting Wang, M. Matsabisa, Min-Ke Tang, 2025, Brain Science)
- Neuroprotective and anticonvulsant effect of trimetazidine in a PTZ-kindling model of mice through modulation of the IL-1β/IL-1R1 and HMGB-1/TLR-4 axis(Shahnawaz Ahmad, Mohammed Samim, Seema Jain, Divya Vohora, Nidhi, 2025, Frontiers in Pharmacology)
- The treatment value of IL-1β monoclonal antibody under the targeting location of alpha-methyl-l-tryptophan and superparamagnetic iron oxide nanoparticles in an acute temporal lobe epilepsy model(Yan-li Wang, Yan-Ling Wang, R. Sun, Xing-Rao Wu, X. Chu, Shu-Hu Zhou, Xi-Bin Hu, Lingyun Gao, Qingxia Kong, 2018, Journal of Translational Medicine)
- Monophosphoryl Lipid A and Pam3Cys Prevent the Increase in Seizure Susceptibility and Epileptogenesis in Rats Undergoing Traumatic Brain Injury(S. Hesam, Baharak Khoshkholgh-Sima, H. G. Pourbadie, V. Babapour, Morteza Zendedel, M. Sayyah, 2018, Neurochemical Research)
- Lamotrigine Ameliorates Epilepsy during Pregnancy in Rats by Inhibiting Astrocyte Activation via the NLRP3/TXNIP Pathway(Cui-Yu You, Ya-Lin Dong, Di Zhang, T. Wang, Wenjuan Zhang, Xiaoye Zhao, Jinyao Sun, 2026, Journal of Neuroimmune Pharmacology)
- The role of crosstalk between cerebral immune cells and peripheral immune cells in the damage and protection of blood-brain barrier after intracerebral hemorrhage(Yi-Hui Wang, Wen-Cao Liu, Jia-Ning Zhang, Pan-pan Geng, Xin-Chun Jin, 2024, Brain Hemorrhages)
- Astrocyte-microglia IL-3-IL-3Rα signaling drives JAK2/STAT5-dependent neuroinflammation and neurodegeneration after status epilepticus.(Li-Ping Xie, Lian Liu, Xu-Tao Wang, Xiao Wang, Bo He, Tiantian Wang, Honghao Xu, Zhi-Lin Li, Shui-Sheng Lei, Xiao-Qin Zhu, 2026, Experimental Brain Research)
- Chronic vagus nerve stimulation (VNS) altered IL-6, IL-1β, CXCL-1 and IL-13 levels in the hippocampus of rats with LiCl-pilocarpine-induced epilepsy.(Renli Qi, Min-Shu Wang, Qian Zhong, Lanlin Wang, Xin-Wang Yang, Baihui Huang, Zhengsheng Yang, Cong Zhang, Xin Geng, Cheng Luo, Wei Wang, Jing-Hui Li, Hua-Lin Yu, Jing-Kuan Wei, 2022, Brain Research)
- Pharmacological modulation of cytokines correlating neuroinflammatory cascades in epileptogenesis(S. Vishwakarma, Shareen Singh, T. G. Singh, 2021, Molecular Biology Reports)
- Neuroinflammation in Pathogenesis of Audiogenic Epilepsy: Altered Proinflammatory Cytokine Levels in the Rats of Krushinsky–Molodkina Seizure-Prone Strain(N. Surina, I. Fedotova, G. Nikolaev, V. V. Grechenko, L. V. Gankovskaya, A. D. Ogurtsova, I. Poletaeva, 2023, Biochemistry (Moscow))
- Formononetin Attenuates Seizure Severity and Cognitive Deficits in PTZ-Kindled Rats with Associated Changes in Oxidative Stress and P2 X 7/IL-1β/Glutamate Signalling Markers(Harsh Yadav, B. Thawkar, Nisarg S. Sawant, 2026, Neurochemical Research)
本综述围绕"同一细胞因子因细胞来源、解剖分区与癫痫发生(致痫)阶段不同而产生不同甚至相反效应,故其净效应不能仅由浓度推断"这一核心命题,将三份初始化分组整合为九个并列的一级板块,形成"概念框架—细胞来源(小胶质细胞/星形胶质细胞/神经元/外周免疫)—解剖界面(BBB与脑-外周通路)—临床表型与转化—情境选择性干预"的完整证据链。合并策略为:(1) 将各分组中所有"细胞因子/介质效应情境依赖性"的总论性、综述性文献统一归入概念框架板块,避免与小胶质/星形胶质专题重复;(2) 小胶质细胞分为"早期应答、细胞因子来源与双向作用"与"补体依赖的病理性突触修剪"两个并列板块,因后者文献集中讨论C1q/C3-吞噬机制,与前者机制方向不同,不宜笼统合并;(3) 星形胶质细胞拆为"谷氨酸摄取—钾缓冲—反应性极化/胶质瘢痕与保护性表型"一个板块,因三份分组均以同一逻辑(转运体/通道失衡放大超兴奋 + 反应性表型可保护)组织,合并后主题仍具体;(4) 神经元源性HMGB1/DAMPs 独立成板块,保留其"炎症起始者"的独特定位;(5) 外周免疫拆为"BBB破坏与单核/巨噬细胞、T细胞浸润的解剖通路与时空差异"与"外周细胞因子/补体/趋化因子谱的临床表型关联"两个板块,对应机制层与临床层;(6) 将原分组中的干预/药理类文献(单抗、中药提取物、曲美他嗪、VNS、TLR配体预处理、拉莫三嗪等)整合为"情境选择性的抗炎与免疫调节干预"板块,涵盖三份分组中散落的治疗学证据,弥补被忽略的"治疗反应随细胞来源而异"论点;(7) 补遗板块"多胶质细胞协同调控抑制性网络与致痫驱动"保留其独特价值。全部 bibkey 均逐字取自提供的初始化分组,未新增或改写。
整合三份分组中所有总论性、综述性文献,共同论证同一炎症介质(IL-1、TNF-α、IL-6、IL-2、NLRP3炎症小体、IL-12家族、HMGB1等危险信号)的神经调控结局不由浓度单独决定,而取决于产生细胞、局部受体环境、空间定位(脑实质、血管周围间隙、脑膜)与致痫进程阶段;为全文所有细胞来源分述提供统一理论支点,是综述的总纲而非某一细胞专题。相关文献:Shuo Liu et. al, 2026 等 10 篇文献
合并三份分组中聚焦小胶质细胞本体功能的文献:一方面以Kv1.3阻断、槲皮素抑制NF-κB、抗TNF-α/抗IL-1β单抗、ATP-腺苷负反馈、MCT4缺失等证据表明其早期活化与细胞因子释放增强谷氨酸能传递、削弱GABA能抑制并加重发作;另一方面通过突触修剪、吞噬与组织修复、密度-活化平衡及综述性"双面性"论述,证明同一细胞在不同情境下可保护神经元,直接支撑效应方向随语境反转的论点。相关文献:Xin-Yi Zhang et. al, 2022 等 14 篇文献
保留为独立板块:这组文献专门讨论补体C1q/C3标记、ATM与吞噬体介导的过度修剪,优先清除抑制性突触、破坏兴奋/抑制平衡并降低惊厥阈值,同时证明恢复ATM或靶向补体-小胶质轴可挽救突触完整性与认知功能。其机制主线(吞噬而非细胞因子分泌)与上一板块不同,合并会使主题笼统化。相关文献:Yu-Lei Sun et. al, 2026 等 3 篇文献
合并三份分组中全部星形胶质细胞文献为单一但具体的板块:GLT-1/GLAST/EAAT2谷氨酸清除(含ADGRV1调控、NEO1缺失、神经元囊泡miR-181c-5p经PKCδ下调GLT-1、IL-1β调控转运体)、GS与Gln-Glu代谢动力学模型、mGluR5条件性敲除、Kir4.1/Kir2.1钾空间缓冲与AQP4/内足脱离、以及A1型极化、GFAP上调、胶质瘢痕电生理与星形胶质MAGL缺失经CB1-PPARγ抑制促炎转化的保护性表型,共同说明同一细胞类型既放大网络兴奋又可限制炎症与神经元损伤。相关文献:Allison R. Peterson et. al, 2020 等 24 篇文献
保留其独特性:这组文献把星形胶质GABA/谷氨酰胺供给、小胶质炎症信号与少突胶质髓鞘重塑整合为"多胶质抑制性可塑性"模型,论证胶质细胞可主动驱动癫痫发生而非仅被动反应,为"同一介质效应取决于贡献它的细胞组合"提供跨细胞类型证据,无法归入单一细胞专题。相关文献:S. Robel et. al, 2015 等 3 篇文献
合并三份分组中的HMGB1模块:证明炎症并非仅由胶质发起——过度兴奋或损伤的神经元使HMGB1核转位并释放至树突与细胞外空间,经TLR4/RAGE-NF-κB激活胶质并招募T细胞,热性惊厥持续状态模型中HMGB1转位与miR-124外释呈现快速时间动态,miR129-5p外泌体、甘草酸及miR-340-5p/IRF1/USP18轴等可干预,并含IL-1β/IL-6/HMGB1基因变异与发作后血清水平关联,支持神经元作为炎症起点兼有个体差异。相关文献:Y. Paudel et. al, 2020 等 10 篇文献
合并三份分组中的BBB与浸润模块:白蛋白外渗经TGF-β驱动星形胶质功能障碍与钾缓冲受损、CD8 T细胞经MHC I限制性机制参与BBB破坏、BBB内皮固有免疫感受器与脑膜淋巴引流、小胶质细胞较浸润髓系细胞促炎性更低、炎性单核细胞与小胶质细胞功能独立、髓系EP2活化、LPS外周炎症与雷帕霉素干预等,系统论证外周免疫细胞在受体谱、细胞因子谱与时间动态上与驻留胶质不同,构成独立的"外周-中枢界面"证据层。相关文献:E. Suleymanova et. al, 2025 等 15 篇文献
合并三份分组中的临床/生物标志物模块:癫痫后CCL2/CCL3/CCL5/IL-1β在不同脑区与时间点的差异表达、药物难治性癫痫患者血清补体的性别特异性改变、儿童耐药性癫痫中IL-1β与GDNF水平同严重度的关系、神经精神共病与发作相关指标,以及外周血单个核细胞活化状态,说明外周免疫谱可作为分型与疗效预测指标,体现"解剖分区与疾病阶段"对介质效应的调制。相关文献:G. M. Arisi et. al, 2015 等 6 篇文献
将三份分组中散落的治疗学文献整合为独立板块,回应"不同细胞来源受体表达与信号阈值不同、对抗炎治疗反应各异"的论点:包括IL-1β单抗的靶向递送价值评估、单磷酰脂质A/Pam3Cys预处理、拉莫三嗪、曲美他嗪、三七花提取物、formononetin、VNS对细胞因子的调节、小胶质-星形胶质IL-3/IL-3R串扰等,说明需按细胞来源、受体环境与疾病阶段分层设计干预,而非采用统一抗炎策略。相关文献:Yang Zhao et. al, 2025 等 11 篇文献
总计 95 篇相关文献
Epilepsy is a chronic neurological disorder whose pathophysiology relates to inflammation. The potassium channel Kv1.3 in microglia has been reported as a promising therapeutic target in neurological diseases in which neuroinflammation is involved, such as multiple sclerosis (MS), Alzheimer’s disease (AD), Parkinson’s disease (PD), and middle cerebral artery occlusion/reperfusion (MCAO/R). Currently, little is known about the relationship between Kv1.3 and epilepsy. In this study, we found that Kv1.3 was upregulated in microglia in the KA-induced mouse epilepsy model. Importantly, blocking Kv1.3 with its specific small-molecule blocker 5-(4-phenoxybutoxy)psoralen (PAP-1) reduced seizure severity, prolonged seizure latency, and decreased neuronal loss. Mechanistically, we further confirmed that blockade of Kv1.3 suppressed proinflammatory microglial activation and reduced proinflammatory cytokine production by inhibiting the Ca2+/NF-κB signaling pathway. These results shed light on the critical function of microglial Kv1.3 in epilepsy and provided a potential therapeutic target.
Epilepsy is a chronic and recurrent disease of the central nervous system, with a complex pathology. Recent studies have demonstrated that the activation of glial cells serve an important role in the development of epilepsy. The objective of the present study was to investigate the role of high-mobility group box-1 (HMGB1) in mediating the activation of glial cells through the toll-like receptor 4 (TLR4)/nuclear factor (NF)-κB signaling pathway in seizure, and the underlying mechanism. The brain tissue of post-surgery patients with intractable epilepsy after resection and the normal control brain tissue of patients with craniocerebral trauma induced intracranial hypertension were collected. The expression level and distribution pattern of HMGB1, OX42 and NF-κB p65 were detected by immunohistochemistry. HMGB1, TLR4, receptor for advanced glycation end products (RAGE), NF-κB p65 and inducible nitric oxide synthase (iNOS) expression levels were detected by western blotting, and serum cytokine levels of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β and IL-10 in patients with epilepsy and craniocerebral trauma were detected by ELISA. And cell model of epilepsy was established by coriaria lactone (CL)-stimulated HM cell, and the same factors were measured. The potential toxic effect of HMGB1 on HM cells was evaluated by MTT and 5-ethynyl-2-deoxyuridine assays. The results demonstrated that compared with the control group, levels of HMGB1, TLR4, RAGE, NF-κB p65 and iNOS in the brain of the epilepsy group were significantly increased, and increased cytokine levels of IL-1, IL-6, TNF-α, TGF-β and IL-10 in patients with epilepsy were also observed. At the same time, the above results were also observed in HM cells stimulated with CL. Overexpression of HMGB1 enhanced the results, while HMGB1 small interfering RNA blocked the function of CL. There was no significant toxic effect of HMGB1 on HM cells. In conclusion, overexpression of HMGB1 potentially promoted epileptogenesis. CL-induced activation of glial cells may act via up-regulation of HMGB1 and TLR4/RAGE receptors, and the downstream transcription factor NF-κB.
Patients with epilepsy face heightened risk of post-ictal cardiorespiratory suppression and sudden unexpected death in epilepsy (SUDEP). Studies have shown that neuroinflammation, mediated by the activation of microglia and astrocytes, may be a cause or consequence of seizure disorders. Kcnj16 (Kir5.1) knockout rats (SS kcnj16−/− ) are susceptible to repeated audiogenic seizures and recapitulate features of human SUDEP, including post-ictal ventilatory suppression, which worsens with repeated seizures and seizure-induced mortality. In this study, we tested the hypothesis that repeated seizures cause neuroinflammation within key brainstem regions that contribute to the control of breathing. Audiogenic seizures were elicited once/day for up to 10 days in groups of adult male SS kcnj16−/− rats, from which frozen brainstem biopsies of the pre-Bötzinger complex/nucleus ambiguus (preBötC/NA), Bötzinger complex (BötC), and raphe magnus (RMg) regions were subjected to a cytokine array. Several cytokines/chemokines, including IL-1α and IL-1ß, were increased selectively in preBötC/NA after 3 or 5 days of seizures with fewer changes in other regions tested. In additional groups of male SS kcnj16−/− rats that underwent repeated seizures, we quantified microglial (IBA-1+) cell counts and morphology, specifically within the preBötC/NA region, and showed increased microglial cell counts, area, and volume consistent with microglial activation. To further test the role of inflammation in physiological responses to seizures and seizure-related mortality, additional groups of SS kcnj16−/− rats were treated with anakinra (IL-1R antagonist), ketoprofen (non-selective COX inhibitor), or saline for 3 days before and up to 10 days of seizures (1/day), and breathing was measured before, during, and after each seizure. Remarkably, IL-1R antagonism mitigated changes in post-ictal ventilatory suppression on days 7–10 but failed to prevent seizure-related mortality, whereas ketoprofen treatment exacerbated post-ictal ventilatory suppression compared to other treatment groups but prevented seizure-related mortality. These data demonstrate neuroinflammation and microglial activation within the key brainstem region of respiratory control following repeated seizures, which may functionally but differentially contribute to the pathophysiological consequences of repeated seizures.
No abstract available
Traumatic brain injury (TBI) is a leading cause of acquired epilepsy, and the latent period before the first spontaneous seizure offers a window for anti-epileptogenic intervention. Glial cells are active participants in the pathophysiology of epilepsy and play a role beyond the classical supportive roles and in the control of inhibitory networks. Cumulatively, astrocytes, microglia and oligodendrocytes contribute to the GABAergic signal transduction via orchestrated pathways comprising neurotransmitter uptake, cytokine-mediated inflammation and myelin remodeling. GABA transporters (GAT-1, GAT-3) mediating astrocytes have a major role in modulation of inhibitory tone, connecting circadian genes (such as Bmal1) to sleep-associated alterations in seizure susceptibility. Microglial reactivity and neuroinflammation also disrupt astrocytic inhibitory homeostasis and promote both epileptogenesis and sleep instability. Oligodendrocytes exert activity-dependent myelination on inhibitory networks, affecting seizure propagation and oscillatory synchrony. However, it is unclear how these glial populations interact to control inhibition for NREM sleep, REM sleep, interictal, ictal, and postictal conditions. We present the results of a multi-glial inhibitory plasticity model in this review to extend on the classical tripartite synapse model to integrate astrocytic GABA transport, microglial inflammatory signaling and oligodendrocyte-driven circuit remodeling. This framework suggests that the glial-mediated modulation of inhibitory homeostasis is a state-specific regulatory mechanism in epilepsy and sleep-associated comorbidities, providing a basis for future treatments focusing on stability of the inhibitory network. Because sleep is disrupted early after TBI, the state-dependent glial control of inhibition described here is directly relevant to post-traumatic epileptogenesis.
Background The pathogenic contribution of neuroinflammation to ictogenesis and epilepsy may provide a therapeutic target for reduction of seizure burden in patients that are currently underserved by traditional anti-seizure medications. The Theiler's murine encephalomyelitis virus (TMEV) model has provided important insights into the role of inflammation in ictogenesis, but questions remain regarding the relative contribution of microglia and inflammatory monocytes in this model. Methods Female C57BL/6 mice were inoculated by intracranial injection of 2 × 10 5 , 5 × 10 4 , 1.25 × 10 4 , or 3.125 × 10 3 plaque-forming units (PFU) of the Daniel’s strain of TMEV at 4–6 weeks of age. Infiltration of inflammatory monocytes, microglial activation, and cytokine production were measured at 24 h post-infection (hpi). Viral load, hippocampal injury, cognitive performance, and seizure burden were assessed at several timepoints. Results The intensity of inflammatory infiltration and the extent of hippocampal injury induced during TMEV encephalitis scaled with the amount of infectious virus in the initial inoculum. Cognitive performance was preserved in mice inoculated with 1.25 × 10 4 PFU TMEV relative to 2 × 10 5 PFU TMEV, but peak viral load at 72 hpi was equivalent between the inocula. CCL2 production in the brain was attenuated by 90% and TNFα and IL6 production was absent in mice inoculated with 1.25 × 10 4 PFU TMEV. Acute infiltration of inflammatory monocytes was attenuated by more than 80% in mice inoculated with 1.25 × 10 4 PFU TMEV relative to 2 × 10 5 PFU TMEV but microglial activation was equivalent between groups. Seizure burden was attenuated and the threshold to kainic acid-induced seizures was higher in mice inoculated with 1.25 × 10 4 PFU TMEV but low-level behavioral seizures persisted and the EEG exhibited reduced but detectable abnormalities. Conclusions The size of the inflammatory monocyte response induced by TMEV scales with the amount of infectious virus in the initial inoculum, despite the development of equivalent peak infectious viral load. In contrast, the microglial response does not scale with the inoculum, as microglial hyper-ramification and increased Iba-1 expression were evident in mice inoculated with either 1.25 × 10 4 or 2 × 10 5 PFU TMEV. Inoculation conditions that drive inflammatory monocyte infiltration resulted in robust behavioral seizures and EEG abnormalities, but the low inoculum condition, associated with only microglial activation, drove a more subtle seizure and EEG phenotype.
Epilepsy is a prevalent neurological disorder and it is a significant health risk, affecting >50 million people worldwide. The development of novel and appropriate strategies is required for ameliorating the progression and/or limiting the detrimental consequences of epilepsy. In the current study, kainic acid (KA), a neurotoxin, was used to induce seizures in mice. The flavonoid quercetin has recently been reported to have neuroprotective effects. Therefore, the effects of quercetin on KA-induced epilepsy and the potential underlying molecular mechanisms were examined. It was noted that quercetin attenuated the KA-induced seizure score and proinflammatory cytokine production, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and activation of nuclear factor κB (NF-κB) in mice. Quercetin attenuated KA-induced proinflammatory cytokine (TNF-α and IL-1β) release from microglia cells, as well as activation of NF-κB and ionized calcium binding adapter molecule 1 in microglia cells. Therefore, quercetin inhibited KA-induced epilepsy by microglia cell inactivation and the production of NF-κB, TNF-α and IL-1β.
No abstract available
BackgroundNeuroinflammation with activation of microglia and production of proinflammatory cytokines in the brain plays an active role in epileptic disorders. Brain oxidative stress has also been implicated in the pathogenesis of epilepsy. Damage in the hippocampus is associated with temporal lobe epilepsy, a common form of epilepsy in human. Peripheral inflammation may exacerbate neuroinflammation and brain oxidative stress. This study examined the impact of peripheral inflammation on seizure susceptibility and the involvement of neuroinflammation and oxidative stress in the hippocampus.ResultsIn male, adult Sprague-Dawley rats, peripheral inflammation was induced by the infusion of Escherichia coli lipopolysaccharide (LPS, 2.5 mg/kg/day) into the peritoneal cavity for 7 days via an osmotic minipump. Pharmacological agents were delivered via intracerebroventricular (i.c.v.) infusion with an osmotic minipump. The level of cytokine in plasma or hippocampus was analyzed by ELISA. Redox-related protein expression in hippocampus was evaluated by Western blot. Seizure susceptibility was tested by intraperitoneal (i.p.) injection of kainic acid (KA, 10 mg/kg). We found that i.p. infusion of LPS for 7 days induced peripheral inflammation characterized by the increases in plasma levels of interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). This is associated with a significant increase in number of the activated microglia (Iba-1+ cells), enhanced production of proinflammatory cytokines (including IL-1β, IL-6 and TNF-α), and tissue oxidative stress (upregulations of the NADPH oxidase subunits) in the hippocampus. These cellular and molecular responses to peripheral inflammation were notably blunted by i.c.v. infusion of a cycloxygenase-2 inhibitor, NS398 (5 μg/μl/h). The i.c.v. infusion of tempol (2.5 μg/μl/h), a reactive oxygen species scavenger, protected the hippocampus from oxidative damage with no apparent effect on microglia activation or cytokine production after peripheral inflammation. In the KA-induced seizure model, i.c.v. infusion of both NS398 and tempol ameliorated the increase in seizure susceptibility in animals succumbed to the LPS-induced peripheral inflammation.ConclusionsTogether these results indicated that LPS-induced peripheral inflammation evoked neuroinflammation and the subsequent oxidative stress in the hippocampus, resulting in the increase in KA-induced seizure susceptibility. Moreover, protection from neuroinflammation and oxidative stress in the hippocampus exerted beneficial effect on seizure susceptibility following peripheral inflammation.
BackgroundCytokines and chemokines play an important role in the neuroinflammatory response to an initial precipitating injury such as status epilepticus (SE). These signaling molecules participate in recruitment of immune cells, including brain macrophages (microglia), as well as neuroplastic changes, deterioration of damaged tissue, and epileptogenesis. This study describes the temporal and brain region pattern expression of numerous cytokines, including chemokines, after pilocarpine-induced seizures and discusses them in the larger context of their potential involvement in the changes that precede the development of epilepsy.FindingsAdult rats received pilocarpine to induce SE and 90 min after seizure onset were treated with diazepam to mitigate seizures. Rats were subsequently deeply anesthetized and brain regions (hippocampus, piriform cortex, neocortex, and cerebellum) were freshly dissected at 2, 6, and 24 h or 5 days after seizures. Using methodology identical to our previous studies, simultaneous assay of multiple cytokines (CCL2, CCL3, CCL5, interleukin IL-1β, tumor necrosis factor (TNF-α)), and vascular endothelial growth factor (VEGF) was performed and compared to control rats. These proteins were selected based on existing evidence implicating them in the epileptogenic progression. A robust increase in CCL2 and CCL3 concentrations in the hippocampus, piriform cortex, and neocortex was observed at all time-points. The concentrations peaked with a ~200-fold increase 24 h after seizures and were two orders of magnitude greater than the significant increases observed for CCL5 and IL-1β in the same brain structures. TNF-α levels were altered in the piriform cortex and neocortex (24 h) and in the hippocampus (5 days) after SE.ConclusionsPilocarpine-induced status epilepticus causes a rapid increase of multiple cytokines in limbic and neocortical regions. Understanding the precise spatial and temporal pattern of cytokines and chemokine changes could provide more viable therapeutic targets to reduce, reverse, or prevent the development of epilepsy following a precipitating injury.
No abstract available
No abstract available
Neuroinflammation contributes to epileptogenesis and ictogenesis. Various signals of neuroinflammation lead to neuronal hyper-excitability. Since an interplay between epilepsy, psychiatric comorbidities and neuroinflammation has been suggested, we explored psychiatric symptoms in epilepsy patients, and the relationship with neuroinflammation. We screened epilepsy patients who were admitted for video-EEG monitoring between July 2019 and December 2020. Enrolled patients were asked to respond to neuropsychiatric questionnaires (Hospital Anxiety and Depression Scale (HADS) and Neuropsychiatric Inventory-Questionnaire (NPI-Q)) on admission. Serum cytokines (IL-1β, IL-2, IL-6, IFN-γ, CCL2, and CCL5) were measured by ELISA on admission, and within 6 h after a seizure. We enrolled 134 patients, and 32 patients (23.9%) had seizures during monitoring. Cytokine levels did not change after seizures, but IL-2 and IL-6 increased in cases of generalized tonic–clonic seizures. The HADS-A score was lower in Q4 of CCL5 (p-value = 0.016) and anxiety was also less common in Q4 of CCL5 (p-value = 0.042). NPI-Q question 4 (depression) severity was higher in CCL2 (p-value = 0.024). This suggested that psychiatric symptoms may also be related to inflammatory processes in epilepsy patients. Further large, standardized studies are necessary to underpin the inflammatory mechanisms in epilepsy and psychiatric symptoms.
Drug-resistant epilepsy (DRE) presents significant challenges in treatment and management. While seizure-related alterations in peripheral immune players are increasingly recognized, the involvement of the immune complement system remains insufficiently explored in DRE. We studied complement components and their relationship to cytokine profiles in serum samples from 46 DRE patients and 45 matched healthy controls. We examined relationships between these molecules and clinical outcomes, including epilepsy duration, intelligence scores, and age. We identified DRE-associated complement decreases, including reduced levels of C1q, Factor H, C4, C4b, C3, and C3b/iC3b, as well as elevated bFGF. DRE females showed dysregulation of the classical complement pathway and lower TNFα and interleukin-8 compared to healthy females. DRE males exhibited dysregulation of the classical, lectin, and terminal complement pathways, with trends of increased CCL2 and CCL5 compared to healthy males. Specific complement and inflammatory markers (C2, IL-8, and IL-9) correlated with full-scale IQ scores in DRE patients. Our study reveals significantly lower levels of circulating complement components in DRE and sex-specific complement dysregulation and cytokine imbalances. These findings suggest an underlying peripheral immune system vulnerability that may be sex-dependent and warrants further investigation in DRE. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-88654-5.
Background and Purpose Febrile seizure (FS) is a unique type of seizure that only occurs during childhood. Genelized epilepsy with febrile seizure plus (GEFS+) is a familial epilepsy syndrome associated with FS and afebrile seizure (AFS). Both seizure types are related to fever, but whether genetic susceptibility to inflammation is implicated in them is still unclear. To analyze the associations between postictal serum cytokine levels and genetic variants in the cytokine genes interleukin (IL)-1β, IL-6, and high mobility group box-1 (HMGB1) in FS and GEFS+. Methods Genotyping was performed in 208 subjects (57 patients with FS, 43 patients with GEFS+, and 108 controls) with the SNaPshot assay for IL-1β-31 (rs1143627), IL-1β-511 (rs16944), IL-6-572 (rs1800796), and HMGB1 3814 (rs2249825). Serum IL-1β, IL-6, and HMGB1 levels were analyzed within 2 hours after seizure attacks using the ELISA in only 68 patients (38 FS, 10 GEFS+, and 20 controls). The allele distribution, genotype distribution, and correlations with serum cytokine levels were analyzed. Results Near-complete linkage disequilibrium exists between IL-1β-31 and IL-1β-511 variants. CT genotypes of these variants were associated with significantly higher postictal serum IL-1β levels than were CC+TT genotypes in FS (both p<0.05). CT genotypes of IL-1β-31 and IL-1β-511 variants were more strongly associated with FS than were CC+TT genotypes (odds ratio=1.691 and 1.731, respectively). For GEFS+, serum IL-1β levels after AFS for CT genotypes of IL-1β-31 and IL-1β-511 were also higher than for CC+TT genotypes. No significant associations were found for IL-6 and HMGB1. Conclusions Genetic variants located in IL-1β-31 and IL-1β-511 promotor regions are correlated with higher postictal IL-1β levels in FS. These results suggest that IL-1 gene cluster variants in IL-1β-31 and IL-1β-511 are a host genetic factor for provoking FS in Korean children.
Microglia are highly adaptable innate immune cells that rapidly respond to damage signals in the brain through adoption of a reactive phenotype and production of defensive inflammatory cytokines. Microglia express a distinct transcriptome, encoding receptors that allow them to dynamically respond to pathogens, damage signals, and cellular debris. Expression of one such receptor, the microglia-specific purinergic receptor P2ry12, is known to be downregulated in reactive microglia. Here, we explore the microglial response to purinergic damage signals in reactive microglia in the TMEV mouse model of viral brain infection and temporal lobe epilepsy. Using two-photon calcium imaging in acute hippocampal brain slices, we found that the ability of microglia to detect damage signals, engage calcium signaling pathways, and chemoattract towards laser-induced tissue damage was dramatically reduced during the peak period of seizures, cytokine production, and infection. Using combined RNAscope in situ hybridization and immunohistochemistry, we found that during this same stage of heightened infection and seizures, microglial P2ry12 expression was reduced, while the pro-inflammatory cytokine TNF-a expression was upregulated in microglia, suggesting that the depressed ability of microglia to respond to new damage signals via P2ry12 occurs during the time when local elevated cytokine production contributes to seizure generation following infection. Therefore, changes in microglial purinergic receptors during infection likely limit the ability of reactive microglia to respond to new threats in the CNS and locally contain the scale of the innate immune response in the brain.
Objective Drug-resistant epilepsy (DRE) poses significant challenges in treatment and management. While seizure-related alterations in peripheral immune players are increasingly recognized, the involvement of the complement system, central to immune function, remains insufficiently explored in DRE. This study aimed to investigate the levels of complement system components and their association with cytokine profiles in patients with DRE. Methods We analyzed serum samples from DRE patients (n = 46) and age- and sex-matched healthy controls (n = 45). Complement components and cytokines were quantified using Multi- and Single-plex ELISA. Statistical analyses examined relationships between complement molecules, cytokines, and clinical outcomes including epilepsy duration, Full-Scale Intelligence Quotient (FSIQ) scores, and age. Results We found common alterations in all DRE cases, including significant complement deficiencies (C1q, Factor H, C4, C4b, C3, and C3b/iC3b) and detectable bFGF levels. DRE females showed significantly lower levels of TNFα and IL-8 compared to healthy females. We observed a trend towards elevated CCL2 and CCL5 levels in DRE males compared to healthy males. These findings suggest potential sex dimorphism in immune profiles. Our analysis also indicated associations between specific complement and inflammatory markers (C2, IL-8, and IL-9) and Full-Scale Intelligence Quotient (FSIQ) scores in DRE patients. Interpretation Our study reveals sex-specific peripheral complement deficiencies and cytokine dysregulation in DRE patients, indicating an underlying immune system vulnerability. These findings provide new insights into DRE mechanisms, potentially guiding future research on complement and cytokine signaling toward personalized treatments for DRE patients.
No abstract available
Astrocyte expression of metabotropic glutamate receptor 5 (mGluR5) is consistently observed in resected tissue from patients with epilepsy and is equally prevalent in animal models of epilepsy. However, little is known about the functional signaling properties or downstream consequences of astrocyte mGluR5 activation during epilepsy development. In the rodent brain, astrocyte mGluR5 expression is developmentally regulated and confined in expression/function to the first weeks of life, with similar observations made in human control tissue. Herein, we demonstrate that mGluR5 expression and function dramatically increase in a mouse model of temporal lobe epilepsy. Interestingly, in both male and female mice, mGluR5 function persists in the astrocyte throughout the process of epileptogenesis following status epilepticus. However, mGluR5 expression and function are transient in animals that do not develop epilepsy over an equivalent time period, suggesting that patterns of mGluR5 expression may signify continuing epilepsy development or its resolution. We demonstrate that, during epileptogenesis, astrocytes reacquire mGluR5-dependent calcium transients following agonist application or synaptic glutamate release, a feature of astrocyte-neuron communication absent since early development. Finally, we find that the selective and conditional knock-out of mGluR5 signaling from astrocytes during epilepsy development slows the rate of glutamate clearance through astrocyte glutamate transporters under high-frequency stimulation conditions, a feature that suggests astrocyte mGluR5 expression during epileptogenesis may recapitulate earlier developmental roles in regulating glutamate transporter function. SIGNIFICANCE STATEMENT In development, astrocyte mGluR5 signaling plays a critical role in regulating structural and functional interactions between astrocytes and neurons at the tripartite synapse. Notably, mGluR5 signaling is a positive regulator of astrocyte glutamate transporter expression and function, an essential component of excitatory signaling regulation in hippocampus. After early development, astrocyte mGluR5 expression is downregulated, but reemerges in animal models of temporal lobe epilepsy (TLE) development and patient epilepsy samples. We explored the hypothesis that astrocyte mGluR5 reemergence recapitulates earlier developmental roles during TLE acquisition. Our work demonstrates that astrocytes with mGluR5 signaling during TLE development perform faster glutamate uptake in hippocampus, revealing a previously unexplored role for astrocyte mGluR5 signaling in hypersynchronous pathology.
Astrocytes are vital cells within the central nervous system (CNS), as they perform a critical role in supporting neurons by providing nutrients, such as lactate for energy, and safeguarding them against the toxicity of excessive neurotransmitters, such as glutamate. This study investigates astrocyte adaptive mechanisms in response to chronic inflammation. The primary aim is to assess the long-term effects of an inflammation-induced environment using a combination of lipopolysaccharide (LPS) and interleukin-1β (IL-1β), on the expression of key genes involved in essential metabolic pathways for astrocyte function, including glutamate metabolism and clearance, lactate synthesis and transport, and glucose metabolism. We observed an upregulation of the glutamate transporter eaat2 (but not eaat1), leading to glutamate accumulation and altered glutamate-glutamine cycling, as well as increased glycolytic activity and lactate production/export via hexokinases (hk1 and hk2) and the mct4 lactate transporter. Interestingly, these mechanisms are reversible, indicating a precisely controlled adaptive system. This investigation facilitated the identification of the signaling pathways involved in astrocyte adaptive responses to stress. This will further guide our investigations towards the more complex domain of resistance and adaptation of CNS in pathophysiological conditions.
Traumatic brain injury (TBI) has a complex and multifactorial pathology and is a major cause of death and disability for humans. Immediately after TBI, astrocytes and microglia react with complex morphological and functional changes known as reactive gliosis to form a glial scar in the area immediately adjacent to the lesion, which is the major barrier to neuronal regeneration. The flavonoid agathisflavone (bis-apigenin), present in Poincianella pyramidalis leaves, has been shown to have neuroprotective, neurogenic, and anti-inflammatory effects, demonstrated in vitro models of glutamate-induced toxicity, neuroinflammation, and demyelination. In this study, we evaluated the effect and mechanisms of agathisflavone in neuronal integrity and in the modulation of gliosis in an ex vivo model of TBI. For this, microdissections from the encephalon of Wistar rats (P6-8) were prepared and subjected to mechanical injury (MI) and treated or not with daily agathisflavone (5 μM) for 3 days. Astrocyte reactivity was investigated by measuring mRNA and expression of GFAP protein in the lesioned area by immunofluorescence and Western blot. The proportion of microglia was determined by immunofluorescence for Iba-1; mRNA expression for inflammasome NRPL3 and interleukin-1 beta (IL-1β) was determined by RT-qPCR. It was observed that lesions in the cortical tissue induced astrocytes overexpressing GFAP in the typical glial scar formed and that agathisflavone modulated GFAP expression at the transcriptional and post-transcriptional levels, which was associated with a reduction of the glial scar. MI induced an increase in the proportion of microglia (Iba-1+), which was not observed in agathisflavone-treated cultures. Moreover, the flavonoid modulated negatively both the NRLP3 and IL-1β mRNA expression that was increased in the lesioned area of the tissue. These findings support the regulatory properties of agathisflavone in the control of the inflammatory response in glial cells, which can impact neuroprotection and should be considered for future studies for TB and other pathological conditions of the central nervous system.
Mesial temporal lobe epilepsy (MTLE) is one of the most common refractory epilepsies and is usually accompanied by a range of brain pathological changes, such as neuronal injury and astrocytosis. Naïve astrocytes are readily converted to cytotoxic reactive astrocytes (A1) in response to inflammatory stimulation, suppressing the polarization of A1 protects against neuronal death in early central nervous system injury. Our previous study found that pro‐inflammatory cytokines and miR‐132‐3p (hereinafter referred to as “miR‐132”) expression were upregulated, but how miR‐132 affected reactive astrocyte polarization and neuronal damage during epilepsy is not fully understood. Here, we aimed to explore the effect and mechanism of miR‐132 on A1 polarization. Our results confirmed that A1 markers were significantly elevated in the hippocampus of MTLE rats and IL‐1β‐treated primary astrocytes. In vivo, knockdown of miR‐132 by lateral ventricular injection reduced A1 astrocytes, neuronal loss, mossy fiber sprouting, and remitted the severity of status epilepticus and the recurrence of spontaneous recurrent seizures. In vitro, the neuronal cell viability and axon length were reduced by additional treatment with A1 astrocyte conditioned media (ACM), and downregulation of astrocyte miR‐132 rescued the inhibition of cell activity by A1 ACM, while the length of axons was further inhibited. The regulation of miR‐132 on A1 astrocytes may be related to its target gene expression. Our results show that interfering with astrocyte polarization may be a breakthrough in the treatment of refractory epilepsy, which may extend to the research of other astrocyte polarization‐mediated brain injuries.
Information exchange between neurons and astrocytes mediated by extracellular vesicles (EVs) is known to play a key role in the pathogenesis of central nervous system diseases. A key driver of epilepsy is the dysregulation of intersynaptic excitatory neurotransmitters mediated by astrocytes. Thus, we investigated the potential association between neuronal EV microRNAs (miRNAs) and astrocyte glutamate uptake ability in epilepsy. Here, we showed that astrocytes were able to engulf epileptogenic neuronal EVs, inducing a significant increase in the glutamate concentration in the extracellular fluid of astrocytes, which was linked to a decrease in glutamate transporter‐1 (GLT‐1) protein expression. Using sequencing and gene ontology (GO) functional analysis, miR‐181c‐5p was found to be the most significantly upregulated miRNA in epileptogenic neuronal EVs and was linked to glutamate metabolism. Moreover, we found that neuronal EV‐derived miR‐181c‐5p interacted with protein kinase C‐delta (PKCδ), downregulated PKCδ and GLT‐1 protein expression and increased glutamate concentrations in astrocytes both in vitro and in vivo. Our findings demonstrated that epileptogenic neuronal EVs carrying miR‐181c‐5p decrease the glutamate uptake ability of astrocytes, thus promoting susceptibility to epilepsy.
Glutamate (Glu) is a crucial excitatory neurotransmitter in the central nervous system that transmits brain information by activating excitatory receptors on neuronal membranes. Physiological studies have demonstrated that abnormal Glu metabolism in astrocytes is closely related to the pathogenesis of epilepsy. The astrocyte metabolism processes mainly involve the Glu uptake through astrocyte EAAT2, the Glu-glutamine (Gln) conversion, and the Glu release. However, the relationship between these Glu metabolism processes and epileptic discharges remains unclear. In this paper, we propose a novel neuron-astrocyte model by integrating the dynamical modeling of astrocyte Glu metabolism processes, which include Glu metabolism in astrocytes consisting of the Glu uptake, Glu-Gln conversion, Glu diffusion, and the resulting Glu release as well as Glu-mediated bidirectional communication between neuron and astrocyte. Furthermore, the influences of astrocyte multiple Glu metabolism processes on the Glu release and dynamics transition of neuronal epileptic discharges are verified through numerical experiments and dynamical analyses from various nonlinear dynamics perspectives, such as time series, phase plane trajectories, interspike intervals, and bifurcation diagrams. Our results suggest that the downregulation expression of EAAT2 uptake, the slowdown of the Glu-Gln conversion rate, and excessively elevated Glu equilibrium concentration in astrocytes can cause an increase in Glu released from astrocytes, which results in the aggravation of epileptic seizures. Meanwhile, neuronal epileptic discharge states transition from bursting to mixed-mode spiking and tonic firing induced by the combination of these abnormal metabolism processes. This study provides a theoretical foundation and dynamical analysis methodology for further exploring the dynamics evolution and physiopathological mechanisms of epilepsy.
Astrocytes regulate and respond to extracellular glutamate levels in the central nervous system (CNS) via the Na+-dependent glutamate transporters glutamate transporter-1 (GLT-1) and glutamate aspartate transporter (GLAST) and the metabotropic glutamate receptors (mGluR) 3 and mGluR5. Both impaired astrocytic glutamate clearance and changes in metabotropic glutamate signaling could contribute to the development of epilepsy. Dysregulation of astrocytic glutamate transporters, GLT-1 and GLAST, is a common finding across patients and preclinical seizure models. Astrocytic metabotropic glutamate receptors, particularly mGluR5, have been shown to be dysregulated in both humans and animal models of temporal lobe epilepsy (TLE). In this review, we synthesize the available evidence regarding astrocytic glutamate homeostasis and astrocytic mGluRs in the development of epilepsy. Modulation of astrocyte glutamate uptake and/or mGluR activation could lead to novel glial therapeutics for epilepsy.
No abstract available
Alzheimer's disease (AD) can increase the risk of epilepsy by up to 10‐fold compared to healthy age‐matched controls. However, the pathological mechanisms that underlie this increased risk are poorly understood. Because disruption in brain glutamate homeostasis has been implicated in both AD and epilepsy, this might play a mechanistic role in the pathogenesis of epilepsy in AD. Prior to the formation of amyloid beta (Aβ) plaques, the brain can undergo pathological changes as a result of increased production of amyloid precursor protein (APP) and Aβ oligomers. Impairments in the glutamate uptake ability of astrocytes due to astrogliosis are hypothesized to be an early event occurring before Aβ plaque formation. Astrogliosis may increase the susceptibility to epileptogenesis of the brain via accumulation of extracellular glutamate and resulting excitotoxicity. Here we hypothesize that Aβ oligomers and proinflammatory cytokines can cause astrogliosis and accumulation of extracellular glutamate, which then contribute to the pathogenesis of epilepsy in AD. In this review article, we consider the evidence supporting a potential role of dysfunction of the glutamate‐glutamine cycle and the astrocyte in the pathogenesis of epilepsy in AD.
Background Epilepsy is a chronic and complex brain disorder characterized by frequent seizures, cognitive impairments, neuroinflammation, oxidative stress, and imbalances in neurotransmitters. Developing an effective therapeutic intervention to target these pathological interventions remains a challenge. Trimetazidine (TMZ), the most commonly known anti-ischemic agent, has emerged as a promising candidate for its role in epilepsy due to its diverse mechanisms of action. This study investigates the neuroprotective, anticonvulsant, anti-inflammatory, antioxidant, and neuromodulatory effects of TMZ in managing epilepsy. Methods Kindling was induced by administering Pentylenetetrazole (30 mg/kg, i.p) to Swiss albino mice on every alternate day; TMZ (5, 10, and 20 mg/k p.o) or sodium valproate (200 mg/kg p.o) was given for 5 weeks. Seizure severity was assessed on the Racine scale, and cognitive function and learning were evaluated using the elevated plus maze and the passive avoidance apparatus. Muscle strength was measured using the rotarod test. Neuroinflammatory biomarkers (IL-1β, IL-1R1, IL-6, NF-κB, TNF-α, HMGB-1, TLR-4), oxidative stress markers (MDA, GSH, SOD, catalase), and neurotransmitter (GABA, glutamate, dopamine, serotonin) levels were estimated in the hippocampus and cerebral cortex using commercially available sandwich ELISA kits. Results TMZ, primarily at 10 and 20 mg/kg, significantly reduced seizure scores and improved the transfer latency, step-down latency, and motor abilities in the PTZ-kindled animals. It significantly reduced proinflammatory molecules IL-1β, IL-1R1, IL-6, NF-κB, TNF-α, HMGB-1, TLR-4. Additionally, it increased antioxidant enzyme activity (GSH, SOD, catalase) while lowering MDA levels and restoring GABA, dopamine, and serotonin levels, as well as suppressing glutamate levels, comparable to VPA at 200 mg/kg/day p.o. Conclusion TMZ, at doses of 10 and 20 mg/kg p.o., demonstrated anticonvulsant and antioxidant activity, suppressed kindling progression, and restored neurotransmitter balance. Furthermore, TMZ has shown anti-inflammatory activity against neuroinflammation during epilepsy.
No abstract available
Glutamate overload triggers synaptic and neuronal loss that potentially contributes to neurodegenerative diseases including Alzheimer’s disease (AD). Glutamate clearance and regulation at synaptic clefts is primarily mediated by glial glutamate transporter 1 (GLT-1). We determined that inflammatory cytokines significantly upregulated GLT-1 through microRNA-181a-mediated post-transcriptional modifications. Unveiling the key underlying mechanisms modulating GLT-1 helps better understand its physiological and pathological interactions with cytokines. Primary murine astrocyte and neuron co-culture received 20 ng/mL IL-1β, TNF-α, or IL-6 for 48 h. Soluble proteins or total RNA were extracted after treatment for further analyses. Treatment with inflammatory cytokines, IL-1β and TNF-α, but not IL-6, significantly increased GLT-1 steady-state levels (p≤0.05) without affecting mRNA levels, suggesting the cytokine-induced GLT-1 was regulated through post-transcriptional modifications. Among the candidate microRNAs predicted to modulate GLT-1, only microRNA-181a was significantly decreased following the IL-1β treatment (p≤0.05). Co-treatment of microRNA-181a mimic in IL-1β-treated primary astrocytes and neurons effectively blocked the IL-1β-induced upregulation of GLT-1. Lastly, we attempted to determine the link between GLT-1 and microRNA-181a in human AD brains. A significant reduction of GLT-1 was found in AD hippocampus tissues, and the ratio of mature microRNA-181a over primary microRNA-181a had an increasing tendency in AD. MicroRNA-181a controls rapid modifications of GLT-1 levels in astrocytes. Cytokine-induced inhibition of microRNA-181a and subsequent upregulation of GLT-1 may have physiological implications in synaptic plasticity while aberrant maturation of microRNA-181a may be involved in pathological consequences in AD.
Temporal lobe epilepsy (TLE) is a common and often refractory brain disease that is closely correlated with inflammation. Alpha-methyl-l-tryptophan (AMT) is recognized as a surrogate marker for epilepsy, characterized by high uptake in the epileptic focus. There are many advantages of using the magnetic targeting drug delivery system of superparamagnetic iron oxide nanoparticles (SPIONs) to treat many diseases, including epilepsy. We hypothesized that AMT and an IL-1β monoclonal antibody (anti-IL-1β mAb) chelated to SPIONs would utilize the unique advantages of SPIONs and AMT to deliver the anti-IL-1β mAb across the blood–brain barrier (BBB) as a targeted therapy. Acute TLE was induced in 30 rats via treatment with lithium-chloride pilocarpine. The effects of plain-SPIONs, anti-IL-1β-mAb-SPIONs, or AMT-anti-IL-1β-mAb-SPIONs on seizure onset were assessed 48 h later. Perl’s iron staining, Nissl staining, immunofluorescence staining and western blotting were performed after magnetic resonance imaging examination. The imaging and histopathology in combination with the molecular biology findings showed that AMT-anti-IL-1β-mAb-SPIONs were more likely to penetrate the BBB in the acute TLE model to reach the targeting location and deliver a therapeutic effect than plain-SPIONs and anti-IL-1β-mAb-SPIONs. This study demonstrated the significance of anti-IL-1β-mAb treatment in acute TLE with respect to the unique advantages of SPIONs and the active location-targeting characteristic of AMT.
No abstract available
Significance Epilepsy, a neurological disorder, is caused by abnormal brain activity due to genetic variances or acquired brain injuries. However, the underlying molecular mechanisms remain elusive. We demonstrate that NEO1, a member of the deleted in colorectal cancer (DCC) family transmembrane proteins, is decreased in human hippocampi of patients with epilepsy. By using a combination of genetic, electrophysiological, biochemical, and molecular biological methods, we show that KO Neo1 in hippocampal astrocytes, but not in neurons, increased epileptiform spikes and seizure susceptibility in mice. Astrocyte-specific KO of Neo1 reduced inhibitory synaptic vesicles and GABAergic synaptic transmission in the hippocampus by impairing the GLAST-mediated glutamate–glutamine cycle. Together, this study reveals a function of NEO1 in hippocampal astrocytes to protect the brain from epilepsy. Epilepsy, a common neurological disorder, is featured with recurrent seizures. Its underlying pathological mechanisms remain elusive. Here, we provide evidence for loss of neogenin (NEO1), a coreceptor for multiple ligands, including netrins and bone morphological proteins, in the development of epilepsy. NEO1 is reduced in hippocampi from patients with epilepsy based on transcriptome and proteomic analyses. Neo1 knocking out (KO) in mouse brains displays elevated epileptiform spikes and seizure susceptibility. These phenotypes were undetectable in mice, with selectively depleted NEO1 in excitatory (NeuroD6-Cre+) or inhibitory (parvalbumin+) neurons, but present in mice with specific hippocampal astrocytic Neo1 KO. Additionally, neurons in hippocampal dentate gyrus, a vulnerable region in epilepsy, in mice with astrocyte-specific Neo1 KO show reductions in inhibitory synaptic vesicles and the frequency of miniature inhibitory postsynaptic current(mIPSC), but increase of the duration of miniature excitatory postsynaptic current and tonic NMDA receptor currents, suggesting impairments in both GABAergic transmission and extracellular glutamate clearance. Further proteomic and cell biological analyses of cell-surface proteins identified GLAST, a glutamate–aspartate transporter that is marked reduced in Neo1 KO astrocytes and the hippocampus. NEO1 interacts with GLAST and promotes GLAST surface distribution in astrocytes. Expressing NEO1 or GLAST in Neo1 KO astrocytes in the hippocampus abolishes the epileptic phenotype. Taken together, these results uncover an unrecognized pathway of NEO1-GLAST in hippocampal GFAP+ astrocytes, which is critical for GLAST surface distribution and function, and GABAergic transmission, unveiling NEO1 as a valuable therapeutic target to protect the brain from epilepsy.
ADGRV1 is the largest member of adhesion G protein-coupled receptor (aGPCR) family. In the cell, aGPCRs have dual roles in cell adhesion and signal transduction. Mutations in ADGRV1 have been linked not only to Usher syndrome (USH), which causes deaf-blindness, but recently also to various forms of epilepsy. While the USH defects are attributed to the loss of fiber links between membranes formed by the extracellular domain of ADGRV1, the pathomechanisms leading to epilepsy remain elusive to date. Here, we study the specific functions of ADGRV1 in astrocytes where it is highest expressed in the nervous system. Affinity proteomics showed the interaction of ADRGV1 with proteins enriched in astrocytes. Dysregulations of cellular processes important in astrocyte function were indicated by the different transcriptomes of patient-derived cells and Adgrv1-deficent mouse hippocampi compared to appropriate controls. Alteration in morphology and reduced numbers of astrocytes in the hippocampus of Adgrv1-deficent mice. Monitoring the glutamate uptake in colorimetric assay and by live cell imaging of a genetic glutamate reporter consistently showed that glutamate uptake from the extracellular environment is significantly reduced in Adgrv1-deficent astrocytes. Expression analyses of key enzymes of the glutamate-glutamine cycle in astrocytes and the glutamate metabolism indicated imbalanced glutamate homeostasis in Adgrv1-deficient astrocytes. Finally, we provide evidence that the supportive function of astrocytes in neuronal development also relies on ADGRV1 expression in astrocytes. Our data collectively provides first insights into the molecular pathophysiology underlying the development of epilepsy associated with mutations in ADGRV1. Highlights ADGRV1 deficiency reduces the number of astrocytes in CA1 and changes the morphology of astrocytes in the hippocampus. ADGRV1 interacts with numerous proteins enriched in astrocytes. Differential transcriptomes revealed differential expression of genes related to glutamate homeostasis and epilepsy in ADGRV1 deficient models. ADGRV1 controls glutamate uptake and regulates homeostasis in astrocytes. ADGRV1 in astrocytes is vital for neuron morphogenesis. First insights into the molecular pathophysiology underlying the development of epilepsy associated with mutations in ADGRV1. Graphical Abstract
Developmental cortical malformations (DCMs) are linked with severe epilepsy and are caused by both genetic and environmental insults. DCMs include several neurological diseases, such as focal cortical dysplasia, polymicrogyria, schizencephaly, and others. Human studies have implicated astrocyte reactivity and dysfunction in the pathophysiology of DCMs, but their specific role is unknown. As astrocytes powerfully regulate glutamate neurotransmission, and glutamate levels are known to be increased in human epileptic foci, understanding the role of astrocytes in the pathological sequelae of DCMs is extremely important. Additionally, recent studies examining astrocyte glutamate uptake in DCMs have reported conflicting results, adding confusion to the field. In this study we utilized the freeze lesion (FL) model of DCM, which is known to induce reactive astrocytosis and cause significant changes in astrocyte morphology, proliferation, and distribution. Using whole-cell patch clamp recording from astrocytes, we recorded both UV-uncaging and synaptically evoked glutamate transporter currents (TCs), widely accepted assays of functional glutamate transport by astrocytes. With this approach, we set out to test the hypothesis that astrocyte membrane properties and glutamate transport were disrupted in this model of DCM. Though we found that the developmental maturation of astrocyte membrane resistance was disrupted by FL, glutamate uptake by individual astrocytes was robust throughout FL development. Interestingly, using an immunolabeling approach, we observed spatial and developmental differences in excitatory amino acid transporter (EAAT) expression in FL cortex. Spatially specific differences in EAAT2 (GLT-1) and EAAT1 (GLAST) expression suggest that the relative contribution of each EAAT to astrocytic glutamate uptake may be altered in FL cortex. Lastly, we carefully analyzed the amplitudes and onset times of both synaptically- and UV uncaging-evoked TCs. We found that in the FL cortex, synaptically-evoked, but not UV uncaging-evoked TCs, were larger in amplitude. Additionally, we found that the amount of electrical stimulation required to evoke a synaptic TC was significantly reduced in the FL cortex. Both of these finding are consistent with increased excitatory input to the FL cortex, but not with changes in how individual astrocytes remove glutamate. Taken together, our results demonstrate that the maturation of astrocyte membrane resistance, local distribution of glutamate transporters, and glutamatergic input to the cortex are altered in the FL model, but that single-cell astrocytic glutamate uptake is robust.
Objectives: One-third of patients experience inadequate seizure control with antiseizure medications. Therefore, safer and more effective therapeutic strategies remain urgently needed. Research evidence indicates that Panax notoginseng flower may exhibit potential antiepileptic properties. The study aimed to investigate the neuroprotective and antiepileptic effects of Panax notoginseng flower (PNF) extract in a chronic pentylenetetrazole (PTZ)-kindled mouse model and explore its potential mechanisms, focusing on glutamate homeostasis. Methods: Chronic epilepsy was induced in ICR mice via repeated subconvulsive PTZ intraperitoneal injections. Following successful kindling, mice were orally treated with PNF (1.5 g/kg or 3 g/kg) for 30 days. Seizure behaviors were scored using Racines scale. Neuronal survival, systemic and cerebral cytokines, hippocampal glutamate levels (in vivo microdialysis with LC-MS/MS analysis), glutamate homeostasis related proteins glutamate transporter-2 (GLT-1), glutamate-aspartate transporter-1 (GLAST), and glutamine synthetase (GS) were investigated. Results: PNF treatment significantly reduced seizure severity and restored neuronal nuclei (NeuN+) cell neurons in the cortex and hippocampal CA1 region of PTZ kindled mice. PNF attenuated systemic and neuroinflammation by lowering interleukin-1ß (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-α) levels and increasing interleukin-10 (IL-10) in serum and brain of PTZ mice. PNF reduced hippocampal glutamate accumulation and upregulated GLT-1, GLAST, and GS expression, which were altered by PTZ stimulation. Conclusions: The PNF extract exhibits significant neuroprotective and antiepileptic effects in PTZ-kindled mice, likely through restoring glutamate homeostasis, and suppressing inflammation. These findings, with further clinical development, support the therapeutic potential of PNF as a complementary approach for epilepsy management.
Neuroinflammation contributes to both epileptogenesis and the associated neurodegeneration, so regulation of inflammatory signaling is a potential strategy for suppressing epilepsy development and pathological progression. Exosomes are enriched in microRNAs (miRNAs), considered as vital communication tools between cells, which have been proven as potential therapeutic method for neurological disease. Here, we investigated the role of miR129-5p-loaded mesenchymal stem cell (MSC)-derived exosomes in status epilepticus (SE) mice model. Mice were divided into four groups: untreated control (CON group), kainic acid (KA)-induced SE groups (KA group), control exosome injection (KA + Exo-con group), miR129-5p-loaded exosome injection (KA + Exo-miR129-5p group). Hippocampal expression levels of miR129-5p, HMGB1, and TLR4 were compared among groups. Nissl and Fluoro-jade B staining were conducted to evaluate neuronal damage. In addition, immunofluorescence staining for IBA-1 and GFAP was performed to assess glial cell activation, and inflammatory factor content was determined by ELISA. Hippocampal neurogenesis was assessed by BrdU staining. The expression of HMGB1 was increased after KA-induced SE and peaking at 48 h, while hippocampal miR129-5p expression decreased in SE mice. Exo-miR129-5p injection reversed KA-induced upregulation of hippocampal HMGB1 and TLR4, alleviated neuronal damage in the hippocampal CA3, reduced IBA-1 + and GFAP + staining intensity, suppressed SE-associated increases in inflammatory factors, and decreased BrdU + cell number in dentate gyrus. Exosomes loaded with miR129-5p can protect neurons against SE-mediated degeneration by inhibiting the pro-inflammatory HMGB1/TLR4 signaling axis.
Background and Rationale: Bi-directional neuronal-glial communication is a critical mediator of normal brain function and is disrupted in the epileptic brain. The potential role of aberrant microglia and astrocyte function during epileptogenesis is important because the mediators involved provide tangible targets for intervention and prevention of epilepsy. Glial activation is intrinsically involved in the generation of childhood febrile seizures (FS), and prolonged FS (febrile status epilepticus, FSE) antecede a proportion of adult temporal lobe epilepsy (TLE). Because TLE is often refractory to treatment and accompanied by significant memory and emotional difficulties, we probed the role of disruptions of glial-neuronal networks in the epileptogenesis that follows experimental FSE (eFSE). Methods: We performed a multi-pronged examination of neuronal-glia communication and the resulting activation of molecular signaling cascades in these cell types following eFSE in immature mice and rats. Specifically, we examined pathways involving cytokines, microRNAs, high mobility group B-1 (HMGB1) and the prostaglandin E2 signaling. We aimed to block epileptogenesis using network-specific interventions as well as via a global anti-inflammatory approach using dexamethasone. Results: (A) eFSE elicited a strong inflammatory response with rapid and sustained upregulation of pro-inflammatory cytokines. (B) Within minutes of the end of the eFSE, HMGB1 translocated from neuronal nuclei to dendrites, en route to the extracellular space and glial Toll-like receptors. Administration of an HMGB1 blocker to eFSE rat pups did not decrease expression of downstream inflammatory cascades and led to unacceptable side effects. (C) Prolonged seizure-like activity caused overall microRNA-124 (miR-124) levels to plunge in hippocampus and release of this microRNA from neurons via extra-cellular vesicles. (D) Within hours of eFSE, structural astrocyte and microglia activation was associated not only with cytokine production, but also with activation of the PGE2 cascade. However, administration of TG6-10-1, a blocker of the PGE2 receptor EP2 had little effect on spike-series provoked by eFSE. (E) In contrast to the failure of selective interventions, a 3-day treatment of eFSE–experiencing rat pups with the broad anti-inflammatory drug dexamethasone attenuated eFSE-provoked pro-epileptogenic EEG changes. Conclusions: eFSE, a provoker of TLE-like epilepsy in rodents leads to multiple and rapid disruptions of interconnected glial-neuronal networks, with a likely important role in epileptogenesis. The intricate, cell-specific and homeostatic interplays among these networks constitute a serious challenge to effective selective interventions that aim to prevent epilepsy. In contrast, a broad suppression of glial-neuronal dysfunction holds promise for mitigating FSE-induced hyperexcitability and epileptogenesis in experimental models and in humans.
Understanding the interplay between the innate immune system, neuroinflammation, and epilepsy might offer a novel perspective in the quest of exploring new treatment strategies. Due to the complex pathology underlying epileptogenesis, no disease-modifying treatment is currently available that might prevent epilepsy after a plausible epileptogenic insult despite the advances in pre-clinical and clinical research. Neuroinflammation underlies the etiopathogenesis of epilepsy and convulsive disorders with Toll-like receptor (TLR) signal transduction being highly involved. Among TLR family members, TLR4 is an innate immune system receptor and lipopolysaccharide (LPS) sensor that has been reported to contribute to epileptogenesis by regulating neuronal excitability. Herein, we discuss available evidence on the role of TLR4 and its endogenous ligands, the high mobility group box 1 (HMGB1) protein, the heat shock proteins (HSPs) and the myeloid related protein 8 (MRP8), in epileptogenesis and post-traumatic epilepsy (PTE). Moreover, we provide an account of the promising findings of TLR4 modulation/inhibition in experimental animal models with therapeutic impact on seizures.
PURPOSE Neuroinflammation and disruption of blood brain barrier (BBB) are important players in epileptogenesis, ictogenesis and pharmacoresistance. In this context, we investigated blood levels of HMGB1 and other inflammatory and BBB markers after generalized and focal to bilateral tonic-clonic seizures in serum, summarized under the term generalized convulsive seizures (GCS). METHODS We included consenting adults who were admitted to the epilepsy monitoring unit. Blood samples were drawn at baseline and immediately after a GCS as well as after 2, 6 and 24 h. We measured leukocytes, c-reactive protein (CRP), the danger-associated molecular patterns (DAMPs) high mobility group box 1 (HMGB1) and S100, receptor of advanced glycation end products (RAGE) alongside the BBB markers intercellular adhesion molecule-1 (ICAM1) and matrix metalloproteinase 9 (MMP9). Noradrenaline and lactate measurements were available from a previous study. P-levels <0.05 were regarded as significant. RESULTS Twenty-eight patients with 28 GCS were included. Leukocytosis occurred immediately after GCS and normalized within two hours (p < 0.001). S100 and HMGB1 both increased by ∼80 % (p < 0.001). MMP9 peaked after six hours with levels at 48.6 % above baseline. RAGE decreased by 17.6 % with a nadir at 24 h. CRP increased by 118 % with a peak at 24 h. ICAM1 remained stable (p = 0.068). Postictal HMGB1 correlated with postictal leukocytosis (r = 0.42; p = 0.025) and with MMP9 levels six hours later (r = 0.374; p = 0.05). Postictal lactate levels correlated with MMP9 at 6 h (r = 0.48; p = 0.01) and CRP at 24 h (r = 0.39; p = 0.04). Postictal noradrenaline correlated with lactate (r = 0.57; p = 0.02) and leukocytes (r = 0.39; p = 0.047). DISCUSSION The serum level of the DAMPs HMGB1 and S100 increase immediately after GCS. The hypothetical mechanism includes central nervous processes, such as glutamate toxicity and ROS release from seizing neurons but also muscular tissues. BBB breakdown is marked by the release of MMP9. Further research is needed to understand the complex interactions between electrical and metabolic stress, neuroinflammation and BBB mechanics in seizures and epilepsy. CONCLUSION Our study reveals signs of inflammation, neuronal damage and transitory disruption of BBB following single GCS, underscoring the widespread and possibily detrimental effects of recurrent seizures on brain properties. The long term impact on the disease course, however, is unclear.
No abstract available
A complex set of inflammatory molecules and their receptors has been described in epileptogenic foci in different forms of pharmacoresistant epilepsies. By activating receptor-mediated pathways in neurons, these molecules have profound neuromodulatory effects that are distinct from their canonical activation of immune functions. Importantly, the neuromodulatory actions of some inflammatory molecules contribute to hyperexcitability in neural networks that underlie seizures. This review summarizes recent findings related to the role of cytokines (IL-1beta and TNF-alpha) and danger signals (HMGB1) in decreasing seizure threshold, thereby contributing to seizure generation and the associated neuropathology. We will discuss preclinical studies suggesting that pharmacological inhibition of specific inflammatory signals may be useful to treat drug-resistant seizures in human epilepsy, and possibly arrest epileptogenesis in individuals at risk of developing the disease.
No abstract available
Introduction: Profound immune disorders are triggered by cell death and subsequent release of danger signals after cardiac arrest (CA). Hypothesis: High mobility group box-1 (HMGB1) is one of the main endogenous mediators released by ischemic cell death. Our goal was to determine whether its inhibition could provide neuroprotection and improve the outcome after experimental CA. Methods: After 10 min of ventricular fibrillation and resuscitation, rabbits either received an administration of saline (CT group, n=10) or glycyrrhizin (GL group, n=10), a direct inhibitor of HMGB1 (4 mg/kg, i.v.). Animals were followed during 3 days after CA to evaluate the neurological dysfunction. Additional animals were submitted to the same protocol with brain withdrawal 2 or 6 h after CA for immune cell count by cytometry. Results: After CA, HMGB1 blood levels was significantly reduced in CT vs GL group (30±7 vs 17±2 ng/ml at t=30 min after CA). The systemic inflammatory response was subsequently attenuated in GL vs CT, as shown by reduced interleukin-6 concentration (231±34 vs 993±331 pg/ml at 180 min, respectively). In the CT group, a rapid accumulation of neutrophils (CD11b+) and T cells (CD3+, CD4+ and CD8+) was also evidenced in the brain after cardiac arrest. GL specifically reduced the influx of T cells (e.g., 2.7±0.3 vs 7.3±2.6% of CD3+ cells in the brain at 6 h after CA in GL vs CT, respectively) without modifying neutrophils counts. This effect was neither related to differences in blood cells counts nor a modification of blood-brain-barrier permeability between groups, which then suggests a specific inhibition of cerebral chemo-attraction of T cells by glycyrrhizin. Those modifications were ultimately associated with a reduction in neuronal cell death (fluorojade C staining), as well as improved neurological recovery in GL vs CT groups (mean neurological dysfunction scores at day 3 = 58±13 vs 100±0 %, respectively). Conclusion: HMGB1 is a major mediator of the cerebral early infiltration by T cells following CA. Its inhibition by glycyrrhizin could be a relevant therapeutic target to prevent the propagation of neurological damages.
A large set of inflammatory molecules and their receptors are induced in epileptogenic foci of patients with pharmacoresistant epilepsies of structural etiologies or with refractory status epilepticus. Studies in animal models mimicking these clinical conditions have shown that the activation of specific inflammatory signallings in forebrain neurons or glial cells may modify seizure thresholds, thus contributing to both ictogenesis and epileptogenesis. The search for mechanisms underlying these effects has highlighted that inflammatory mediators have CNS-specific neuromodulatory functions, in addition to their canonical activation of immune responses for pathogen recognition and clearance. This review reports the neuromodulatory effects of inflammatory mediators and how they contribute to alter the inhibitory/excitatory balance in neural networks that underlie seizures. In particular, we describe key findings related to the ictogenic role of prototypical inflammatory cytokines (IL-1β and TNF) and danger signals (HMGB1), their modulatory effects of neuronal excitability, and the mechanisms underlying these effects. It will be discussed how harnessing these neuromodulatory properties of immune mediators may lead to novel therapies to control drug-resistant seizures.
No abstract available
The blood–brain barrier (BBB) is essential for maintaining cerebral homeostasis, and its dysfunction is increasingly recognized as an active driver of epilepsy. This review explores the mechanisms by which BBB disruption contributes to seizures and the development of chronic epilepsy. Potentially epileptogenic insults, including traumatic brain injury, stroke, and status epilepticus, induce acute and often persistent BBB leakage. This breach permits the extravasation of serum albumin, which activates transforming growth factor-beta (TGF-β) signaling in astrocytes. This cascade leads to astrocytic dysfunction, impaired potassium buffering, neuroinflammation, and synaptic remodeling, collectively fostering neuronal hyperexcitability. Furthermore, BBB disruption facilitates the infiltration of peripheral immune cells, amplifying neuroinflammation and propagating a pathologic cycle of BBB damage and seizure activity. BBB damage is mediated by multiple processes, including the activation of the plasminogen activation (PA) system. Furthermore, these processes of BBB disruption and neuroinflammation provide a shared pathological basis for neuropsychiatric disorders like depression and anxiety, which are common comorbidities of epilepsy, through shared mechanisms of neuroinflammation and neurovascular unit (NVU) dysregulation. BBB dysfunction can also contribute to the resistance to antiepileptic drugs. Finally, we discuss the therapeutic potential of stabilizing the BBB as a viable strategy for developing disease-modifying therapies for epilepsy.
Accumulating evidence has demonstrated that the pathogenesis of epilepsy is linked to neuroinflammation and cerebrovascular dysfunction. Peripheral immune cell invasion into the brain, along with these responses, is implicitly involved in epilepsy. This review explored the current literature on the association between the peripheral and central nervous systems in the pathogenesis of epilepsy, and highlights novel research directions for therapeutic interventions targeting these reactions. Previous experimental and human studies have demonstrated the activation of the innate and adaptive immune responses in the brain. The time required for monocytes (responsible for innate immunity) and T cells (involved in acquired immunity) to invade the central nervous system after a seizure varies. Moreover, the time between the leakage associated with blood–brain barrier (BBB) failure and the infiltration of these cells varies. This suggests that cell infiltration is not merely a secondary disruptive event associated with BBB failure, but also a non-disruptive event facilitated by various mediators produced by the neurovascular unit consisting of neurons, perivascular astrocytes, microglia, pericytes, and endothelial cells. Moreover, genetic manipulation has enabled the differentiation between peripheral monocytes and resident microglia, which was previously considered difficult. Thus, the evidence suggests that peripheral monocytes may contribute to the pathogenesis of seizures.
BACKGROUND Rapamycin (RAP), as a Mammalian Target of Rapamycin (mTOR) inhibitor, has a certain antiepileptic effect. The blood-brain barrier (BBB), neuroinflammation, lymphocyte immune cells, and neuronal apoptosis play an obligatory role in the course of a seizure. The aim of this study is to probe whether the antiepileptic mechanism of RAP involves the blood-brain barrier, neuroinflammation, lymphocytes, and neuronal apoptosis. METHODS First, we established a rat epilepsy model by injecting lithium chloride and pilocarpine into the rats (intraperitoneal injection). Then the epileptic rats were treated with different doses of RAP (1 mg/kg.d, 2 mg/kg.d, 4 mg/kg.d). Peripheral blood, brain tissue, and temporal lobe tissue were collected. The levels of blood-brain barrier-related proteins and inflammatory cytokines in the peripheral blood of rats were measured by enzyme-linked immunosorbent assay (ELISA). The effect of RAP on T cell subsets in epileptic rats was analyzed by flow cytometry. The apoptosis of neurons and glial cells in the temporal lobe of rats was analyzed by immunohistochemistry. RESULTS This study found that RAP reduces the levels of BBB-interrelated proteins (matrix metallopeptidase 9 (MMP-9), MMP-2, tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2) and inflammatory cytokines (interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α)) in epileptic rats compared to the model group (p < 0.05). RAP increases the level of total T cells (CD3+CD45+) and T helper cells (CD3+CD4+), decreases the level of cytotoxic T lymphocytes (CD3+CD8+), and inhibits the apoptosis of neurons and glial cells in the temporal lobe compared to the model group (p < 0.05). CONCLUSIONS The antiepileptic mechanism of RAP may be to restore BBB dysfunction, reduce the inflammatory response, balance T cell subsets, and inhibit neuronal and glial cell apoptosis in temporal lobe epilepsy lesions.
No abstract available
No abstract available
Epilepsy is the second most typical chronic disorder, described by recurrent seizures and uncontrolled electrical signaling from neurons in the cerebral cortex. Stimulated astrocytes, along with microglia, promote cytokines that cause neuroinflammation, leading to a chain reaction of subsequent steps involving neurons as well as endothelial cells along the blood-brain barrier. Inflammation in the brain’s neural network can cause convulsions and epilepsy. The migration of albumin proteins and the infiltration of peripheral immune cells from the serum into the brain disrupt BBB, which, in turn, activates astrocytes and microglia, which stimulate pro-inflammatory mediators like cytokines, chemokines, and other inflammatory mediators. They increase the glutamate level and cause an influx of calcium ions, leading to the production of less GABA and a decrease in the influx of chloride ions. These events exacerbate the inflammatory process that leads to neuronal excitability and contribute further to the development of epilepsy. In this review, we discuss how astrocytes, microglia, and neurons stimulate cytokines, chemokines, and other inflammatory mediators that play an essential role in the development of epilepsy. This review also explore how the permeability of the blood-brain barrier promotes neuroinflammation and contributes to epileptogenesis. The purpose of this review is to present knowledge on neuroinflammation so that new antiepileptic drugs can be developed to prevent this disorder.
The influx of immune cells and serum proteins from the periphery into the brain due to a dysfunctional blood‐brain barrier (BBB) has been proposed to contribute to the pathogenesis of seizures in various forms of epilepsy and encephalitis. We evaluated the pathophysiological impact of activated peripheral blood mononuclear cells (PBMCs) and serum albumin on neuronal excitability in an in vitro brain preparation.
Epilepsy is increasingly recognized as a disorder not only of neuronal dysfunction but also of immune dysregulation within the central nervous system (CNS). Accumulating evidence points to a critical role for the immune microenvironment in shaping epileptogenesis—the process that underlies the development and progression of epilepsy. In this Review, we examine the spatial dynamics of neuroimmune interactions, highlighting how local inflammatory niches emerge and evolve across brain compartments such as the parenchyma and perivascular space. We describe how the spatial organization and activation of resident glial cells, alongside the infiltration of peripheral immune cells facilitated by blood–brain barrier (BBB) disruption, contribute to region-specific patterns of neuroinflammation. Critically, we emphasize that understanding “where” these neuroimmune interactions occur—their precise spatial organization within distinct cellular microenvironments—is as fundamental as identifying “what” immune cells are involved or “how” they function. Particular focus is given to the localized actions of immune mediators, including regulatory T cells and pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, and their influence on neuronal excitability. We also discuss the spatiotemporal heterogeneity of immune signatures across different epilepsy syndromes, drawing from both experimental models and clinical observations. Finally, we explore emerging therapeutic strategies that target spatially defined immune responses and consider the potential of spatial biomarkers and advanced tissue-mapping technologies to refine disease classification and guide precision therapies. By positioning the spatial immune landscape as a central feature of epileptogenesis, we propose a framework for developing effective, potentially curative interventions for epilepsy.
Despite advances in pharmacotherapy, approximately one-third of individuals with epilepsy develop drug-resistant epilepsy (DRE), accounting for a disproportionate share of the global disease burden. Emerging evidence implicates dysfunction of the meningeal lymphatic system-a critical regulator of waste clearance and immune surveillance-in the pathogenesis of DRE. This suggests that impaired lymphatic drainage may represent a novel mechanistic pathway and therapeutic target. In this review, we systematically examine the interplay between the lymphatic drainage and neural networks in epileptogenesis. We map the neuroimmunological landscape, delineate the crosstalk between peripheral immune cells and resident glia in central nervous system (CNS), and evaluate how blood-brain barrier disruption contributes to seizure progression. Central to our synthesis is the "lymphatic drainage-neural network" paradigm, through which we characterize dynamic alterations in the glymphatic system (GS) and meningeal lymphatic vessels (mLVs) across ictal and interictal states. We further explore how these systems drive epilepsy-associated comorbidities and assess emerging therapeutic strategies aimed at restoring lymphatic function. We conclude by highlighting the critical role of the meningeal lymphatic system, particularly the GS, in fostering epileptogenesis. While direct experimental evidence linking mLVs to epilepsy remains nascent, their established contribution of the impaired immune surveillance and dysfunctional cerebral lymphatic drainage to diverse CNS disorders strongly positions them-alongside the GS-as compelling therapeutic targets. We advocate for intensified investigation into the lymphatic drainage system as an active and indispensable frontier in epilepsy research.
PURPOSE Investigating immune cells in autoimmune limbic encephalitis (LE) will contribute to our understanding of its pathophysiology and may help to develop appropriate therapies. The aim of the present study was to analyze immune cells to reveal underlying immune signatures in patients with temporal lobe epilepsy (TLE) with LE. METHODS We investigated 68 patients with TLE with LE compared with 7 control patients with TLE with no signs of LE screened from 154 patients with suspected LE. From the patients with TLE-LE, we differentiated early seizure onset (<20 years, n = 9) and late seizure onset group (≥20 years, n = 59) of patients. Patients underwent neuropsychological assessment, electroencephalography (EEG), brain magnetic resonance imaging (MRI), and peripheral blood (PB) and cerebrospinal fluid (CSF) analysis including flow cytometry. RESULTS We identified a higher CD4/8+ T-cell ratio in the PB in all patients with TLE-LE and in patients with late-onset TLE-LE each compared with controls (Kruskal-Wallis one-way ANOVA (analysis of variance) with Dunn's test, p < 0.05). Moreover, a lower CD4/CD8+ T-cell ratio is detected in all patients with TLE-LE with blood-CSF barrier dysfunction, unlike in those with none (Kruskal-Wallis one-way ANOVA with Dunn's test, p < 0.05). CONCLUSIONS These findings suggest that the proportion of CD4+ and CD8+ T-cells in the CSF of patients with LE associated with blood-CSF barrier dysfunction plays a potential role in CNS (central nervous system) inflammation in these patients. Thus, flow cytometry as a methodology reveals novel insights into LE's genesis and symptomatology. The CD4/8+ T-cell ratio in PB as a biomarker for LE requires further investigation.
Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus Varvel NH, Espinosa-Garcia C, Hunter-Chang S, Chen Di, Biegel A, Hsieh A, Blackmer-Raynolds L, Ganesh T, Dingledine R. J Neurosci. 2021;41(5):1105-1117. doi: 10.1523/JNEUROSCI.2040-20.2020 A multidimensional inflammatory response ensues after status epilepticus (SE), driven partly by cyclooxygenase-2-mediated activation of prostaglandin EP2 receptors. The inflammatory response is typified by astrocytosis, microgliosis, erosion of the blood–brain barrier (BBB), formation of inflammatory cytokines, and brain infiltration of blood-borne monocytes. Our previous studies have shown that inhibition of monocyte brain invasion or systemic administration of an EP2 receptor antagonist relieves multiple deleterious consequences of SE. Here, we identify those effects of EP2 antagonism that are reproduced by conditional ablation of EP2 receptors in immune myeloid cells and show that systemic EP2 antagonism blocks monocyte brain entry in male mice. The induction of hippocampal interleukin-6 after pilocarpine SE was nearly abolished in EP2 conditional knockout (KO) mice. Serum albumin levels in the cortex, a measure of BBB breakdown, were significantly higher after SE in EP2-sufficient mice but not in EP2 conditional KOs. The EP2 deficiency in innate immune cells accelerated the recovery from sickness behaviors following SE. Surprisingly, neurodegeneration was not alleviated in myeloid conditional KOs. Systemic EP2 antagonism prevented monocyte brain infiltration and provided broader rescue of SE-induced effects than myeloid EP2 ablation, including neuroprotection and broader suppression of inflammatory mediators. Reporter expression indicated that the cellular target of CD11b-driven Cre was circulating myeloid cells but, unexpectedly, not microglia. These findings indicate that activation of EP2 receptors on immune myeloid cells drives substantial deficits in behavior and disrupts the BBB after SE. The benefits of systemic EP2 antagonism can be attributed, in part, to blocking brain recruitment of blood-borne monocytes. SIGNIFICANCE STATEMENT Unabated seizures reduce quality of life, promote the development of epilepsy, and can be fatal. We previously identified activation of prostaglandin EP2 receptors as a driver of undesirable consequences of seizures. However, the relevant EP2-expressing cell types remain unclear. Here we identify peripheral innate immune cells as a driver of the EP2-related negative consequences of seizures. Removal of EP2 from peripheral immune cells was beneficial, abolishing production of a key inflammatory cytokine, accelerating weight regain, and limiting behavioral deficits. These findings provide evidence that EP2 engagement on peripheral immune and brain endothelia contributes to the deleterious effects of SE, and will assist in the development of beneficial therapies to enhance quality of life in individuals who suffer prolonged seizures.
Activated microglia, astrogliosis, expression of pro‐inflammatory cytokines, blood brain barrier (BBB) leakage and peripheral immune cell infiltration are features of mesial temporal lobe epilepsy. Numerous studies correlated the expression of pro‐inflammatory cytokines with the activated morphology of microglia, attributing them a pro‐epileptogenic role. However, microglia and myeloid cells such as macrophages have always been difficult to distinguish due to an overlap in expressed cell surface molecules. Thus, the detrimental role in epilepsy that is attributed to microglia might be shared with myeloid infiltrates. Here, we used a FACS‐based approach to discriminate between microglia and myeloid infiltrates isolated from the hippocampus 24 h and 96 h after status epilepticus (SE) in pilocarpine‐treated CD1 mice. We observed that microglia do not express MHCII whereas myeloid infiltrates express high levels of MHCII and CD40 96 h after SE. This antigen‐presenting cell phenotype correlated with the presence of CD4pos T cells. Moreover, microglia only expressed TNFα 24 h after SE while myeloid infiltrates expressed high levels of IL‐1β and TNFα. Immunofluorescence showed that astrocytes but not microglia expressed IL‐1β. Myeloid infiltrates also expressed matrix metalloproteinase (MMP)−9 and 12 while microglia only expressed MMP‐12, suggesting the involvement of both cell types in the BBB leakage that follows SE. Finally, both cell types expressed the phagocytosis receptor Axl, pointing to phagocytosis of apoptotic cells as one of the main functions of microglia. Our data suggests that, during early epileptogenesis, microglia from the hippocampus remain rather immune supressed whereas myeloid infiltrates display a strong inflammatory profile. GLIA 2016 GLIA 2016;64:1350–1362
No abstract available
No abstract available
Disruption to the blood brain barrier (BBB) is a leading factor associated with the development of postoperative cognitive dysfunction (POCD). Despite this, the underlying mechanism by which BBB disruption promotes POCD in the elderly population has not yet been not fully elucidated. In this study, we established a POCD mice model using isoflurane, and observed the highly expressed occludin and claudin 5 in brain tissues concomitant with the increased enrichment of CD4 positive cells and NK cells in the hippocampus of POCD mice compared to normal and non-POCD control. Our data suggests that peripheral immune cells may participate in the inflammatory reaction within the hippocampus, following the administration of anesthesia via inhalation with the destruction of the blood-brain barrier.
Cerebral endothelial cells (CEC) that form the brain capillaries are the principal constituents of the blood brain barrier (BBB), the main active interface between the blood and the brain which plays a protective role by restricting the infiltration of pathogens, harmful substances and immune cells into the brain while allowing the entry of essential nutrients. Aberrant CEC function often leads to increased permeability of the BBB altering the bidirectional communication between the brain and the bloodstream and facilitating the extravasation of immune cells into the brain. In addition to their role as essential gatekeepers of the BBB, CEC exhibit immune cell properties as they can receive and transmit signals between the blood and the brain partly via release of inflammatory effectors in pathological conditions. Cerebral endothelial cells express innate immune receptors, including toll like receptors (TLRs) and inflammasomes which are the first sensors of exogenous or endogenous dangers and initiators of immune and inflammatory responses which drive neural dysfunction and degeneration. Accumulating evidence indicates that activation of TLRs and inflammasomes in CEC compromises BBB integrity, promotes aberrant neuroimmune interactions and modulates both systemic and neuroinflammation, common pathological features of neurodegenerative and psychiatric diseases and central nervous system (CNS) infections and injuries. The goal of the present review is to provide an overview of the pivotal roles played by TLRs and inflammasomes in CEC function and discuss the molecular and cellular mechanisms by which they contribute to BBB disruption and neuroinflammation especially in the context of traumatic and ischemic brain injuries and brain infections. We will especially focus on the most recent advances and literature reports in the field to highlight the knowledge gaps. We will discuss future research directions that can advance our understanding of the central contribution of innate immune receptors to CEC and BBB dysfunction and the potential of innate immune receptors at the BBB as promising therapeutic targets in a wide variety of pathological conditions of the brain.
Blood–brain barrier (BBB) disruption is a hallmark of many neurological diseases. It is known that proinflammatory cytokines can disrupt tight junctions between endothelial cells of the BBB, allowing larger molecules to penetrate the brain. Along with BBB disruption, these diseases also feature increased numbers of CD8 T cells as components of the immune cell population in the brain. In this review, we discuss the mechanisms of CD8 T cell-mediated BBB disruption, including the roles of antigen presentation through MHC class I molecules, which emerge as an important determining feature of BBB disruption and immune cell infiltration into the brain.
The NLRP3 inflammasome is a central regulator of innate immunity and inflammation, but its functions extend beyond a simple pro-inflammatory role. Increasing evidence indicates that the biological consequences of NLRP3 activation are highly context-dependent, with protective or pathogenic effects determined by cellular composition, tissue microenvironment, and disease stage. In this review, we examine NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functional shifts. We further discuss three major determinants of NLRP3 output: cytokine bias between IL-1β and IL-18, cell-fate decisions between pyroptosis and survival, and epigenetic programming of inflammasome-responsive states. Using representative disease settings such as cancer, inflammatory bowel disease, and autoimmune disorders, we illustrate how similar NLRP3 activation can lead to divergent biological outcomes. We also discuss the therapeutic implications of this plasticity, arguing that effective intervention will require context-selective rather than universal inhibition. A more precise understanding of NLRP3 context dependence may support rational trial design, biomarker development, future patient-stratification frameworks, and more biologically informed therapeutic strategies in NLRP3-related diseases.
Interleukin 2 (IL-2) is a key homeostatic cytokine, with potential therapeutic applications in both immunogenic and tolerogenic immune modulation. Clinical application has been hampered by pleiotropic functionality and wide-spread receptor expression, with unexpected adverse events during trials. To characterize the IL-2 homeostatic network, we developed a novel mouse strain allowing IL-2 production to be diverted. Rewiring of IL-2 production to diverse leukocyte sources allowed the identification of contextual influences over IL-2 impact. Network analysis identified a priority access for Tregs, and a competitive fitness cost induced among both Tregs and conventional CD4 T cells for IL-2 production. CD8 T cells and NK cells, by contrast, exhibited a preference for autocrine IL-2 production. IL-2 sourced from dendritic cells amplified the Treg circuit, while IL-2 produced by B cells induced two context-dependent circuits: dramatic expansion of CD8+ Tregs and ILC2 cells. The former was associated with an unexpected concentration of rare CD8+ Tregs in B cell zones, while the latter drove a downstream, IL-5-mediated, eosinophilic circuit. The source-specific effects demonstrate the contextual influence of IL-2 function and potentially explain unexpected adverse effects observed during clinical trials of exogenous IL-2. Targeted IL-2 production therefore has the potential to amplify or quench particular circuits in the IL-2 network, based on clinical desirability. Graphical abstract
ABSTRACT Cardiovascular diseases (CVDs) are increasingly recognized as immune-mediated disorders in which cytokines regulate leukocyte recruitment, activation, and tissue repair. This review summarizes the roles of the interleukin-12 (IL-12) cytokine family, including IL-12, interleukin-23 (IL-23), interleukin-27 (IL-27), and interleukin-35 (IL-35), in vascular and myocardial pathology. We highlight the heterodimeric structure and shared-subunit biology of these cytokines, which produce overlapping receptor usage and downstream Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling, contributing to substantial functional pleiotropy. Mechanistic evidence is reviewed showing how IL-12 family cytokines regulate endothelial activation, adhesion pathways, leukocyte recruitment, macrophage polarization, and immune-stromal crosstalk, thereby influencing extracellular matrix turnover and cardiovascular remodeling. Disease-specific findings are discussed in atherosclerosis, angiotensin II-associated hypertension, myocardial infarction, pulmonary hypertension, and diabetic cardiomyopathy. Across these conditions, cytokines may exert either protective or pathogenic effects depending on timing, cellular source, receptor context, and tissue environment. We further examine translational implications for biomarker development and therapeutic targeting, emphasizing the challenge of distinguishing prognostic associations from causal signaling. Overall, IL-12 family cytokines act as context-dependent immunoregulatory nodes in CVD.
Neuroprotection in childhood developmental and epileptic encephalopathies may require approaches, distinct from adult brain injury models of neuroprotection, with a primary focus on preservation of synaptic density rather than prevention of cellular necrosis. There is growing evidence to indicate early-life seizures activate complement cascade proteins C1q and C3. Subsequently, localized microglia may excessively phagocytose structurally intact synaptic neurons disrupting normal brain maturation. This review incorporates kinetic models of neuro-immune interactions based on human histopathology from epileptogenic tissues and quantitative neuro-immune biomarkers to provide suggestions that complement-mediated synaptic pruning may contribute to structural network disruption and cognitive decline in pediatric epilepsy. While standard anti-seizure medications effectively stabilize electrical activity, they do not mitigate underlying neuro-inflammatory responses. Consequently, targeted pharmacological inhibition of the complement microglia axis may provide a potential disease modifying strategy to protect developing neural circuits. The translational feasibility of using targeted complement inhibitors should be evaluated addressing critical challenges such as central nervous system drug delivery across the blood–brain barrier, immunosuppression management and the application of non-invasive biomarkers to define the precise therapeutic window for intervention.
Epilepsy affects around 70 million people worldwide, and roughly one-third of them respond poorly to standard antiepileptic drugs. Current treatments are directed almost entirely at neurons, leaving the contribution of non-neuronal cells largely unaddressed. Microglia, the resident immune cells of the central nervous system, both support neuronal survival and shape neural circuits by pruning synapses through “eat-me” and “don’t-eat-me” signals. In epilepsy, this pruning becomes dysregulated: microglia preferentially eliminate inhibitory synapses, producing excitatory/inhibitory (E/I) imbalance, synchronized network discharges, and a lowered seizure threshold. This review summarizes recent work on pathological synaptic pruning by microglia in epilepsy, focusing on the signaling pathways that drive the process and on whether they can be targeted therapeutically in drug-resistant epilepsy. The broader goal is to suggest new treatment directions beyond conventional, neuron-targeted pharmacology.
Microglial cells account for 5% to 13% of the total cell population in the central nervous system (CNS). In the mature CNS, microglia are capable of self-renewal and can rapidly proliferate in response to injury. A primary function of microglial cells is the initiation and maintenance of the immune response, alongside key roles in inducing inflammation, maintaining brain homeostasis, and regulating neuronal networks. The diverse functions of microglia include the control of neurogenesis and synaptic pruning, as well as providing trophic support to neurons. This review systematizes data on the morphological, molecular-biochemical, and physiological changes in microglia following exposure to ionizing radiation, considering the dose and quality of the radiation. It examines the specific morphological, molecular, biochemical, and physiological processes occurring in microglia under exposure to various radiation doses. Additionally, the review presents data on microglial functioning associated with the long-term effects of different radiation doses and the impact of irradiation on cognitive functions.
Structural and functional collapse of the balance between excitatory (E) and inhibitory (I) synapses, i.e., synaptic E/I balance, underlies the pathogeneses of various central nervous system (CNS) disorders. In epilepsy, the synaptic E/I balance tips toward excitation; thus, most of the existing epileptic remedies have focused on how to directly suppress the activity of neurons. However, because as many as 30% of patients with epilepsy are drug resistant, the discovery of new therapeutic targets is strongly desired. Recently, the roles of glial cells in epilepsy have gained attention because glial cells manipulate synaptic structures and functions in addition to supporting neuronal survival and growth. Among glial cells, microglia, which are brain-resident immune cells, have been shown to mediate inflammation, neuronal death and aberrant neurogenesis after epileptic seizures. However, few studies have investigated the involvement of synaptic pruning—one of the most important roles of microglia—in the epileptic brain. In this review, we propose and discuss the hypothesis that synaptic pruning by microglia is enhanced in the epileptic brain, drawing upon the findings of previous studies. We further discuss the possibility that aberrant synaptic pruning by microglia induces synaptic E/I imbalance, promoting the development and aggravation of epilepsy.
Microglia, the innate immune cells of the central nervous system, actively participate in brain development by supporting neuronal maturation and refining synaptic connections. These cells are emerging as highly metabolically flexible, able to oxidize different energetic substrates to meet their energy demand. Lactate is particularly abundant in the brain, but whether microglia use it as a metabolic fuel has been poorly explored. Here we show that microglia can import lactate, and this is coupled with increased lysosomal acidification. In vitro, loss of the monocarboxylate transporter MCT4 in microglia prevents lactate-induced lysosomal modulation and leads to defective cargo degradation. Microglial depletion of MCT4 in vivo leads to impaired synaptic pruning, associated with increased excitation in hippocampal neurons, enhanced AMPA/GABA ratio, vulnerability to seizures and anxiety-like phenotype. Overall, these findings show that selective disruption of the MCT4 transporter in microglia is sufficient to alter synapse refinement and to induce defects in mouse brain development and adult behavior.
Microglia are the resident immune cells of the central nervous system, highly sensitive to oxidative stress and essential for maintaining synaptic homeostasis. While epilepsy induces profound redox imbalance, how oxidative stress reshapes microglial function and disrupts synaptic integrity remains unclear. Here we show that epileptic seizures drive early loss of ataxia-telangiectasia mutated (ATM) protein in microglia, independent of canonical DNA damage responses. ATM deficiency shifts microglia into a hyperphagocytic state, with morphological activation and aberrant synaptic engulfment. Single-nucleus transcriptomic analysis of human temporal lobe epilepsy samples reveals that microglial subpopulations with reduced ATM expression display transcriptional signatures of activation, enhanced lysosomal processing, and synapse remodeling, accompanied by extensive rewiring of ligand-receptor interactions with neurons. Restoring ATM in microglia attenuates aberrant phagocytic activity and rescues synaptic integrity and cognitive function. Mechanistically, ATM sustains CREB phosphorylation to maintain G6PD-dependent NADPH production and antioxidant capacity, the disruption of which precipitates mitochondrial oxidative injury and excessive microglial synaptic pruning. Together, our findings reveal a DNA damage-independent ATM-CREB-G6PD axis that limits oxidative stress and maladaptive microglial phagocytosis, highlighting ATM loss as a key driver of synaptic pathology in epilepsy.
The microglia, first identified by Pío del Río-Hortega, are resident macrophages in the CNS that aid in immune monitoring, synaptic remodeling, and tissue repair. Microglial biology’s dual functions in maintaining homeostasis and contributing to neurodegeneration are examined in this review, with a focus on neurodegenerative disease treatment targets. Methods: We reviewed microglial research using single-cell transcriptomics, molecular genetics, and neuroimmunology to analyze heterogeneity and activation states beyond the M1/M2 paradigm. Results: Microglia maintains homeostasis through phagocytosis, trophic factor production, and synaptic pruning. They acquire activated morphologies in pathological conditions, releasing proinflammatory cytokines and reactive oxygen species via NF-κB, MAPK, and NLRP3 signaling. Single-cell investigations show TREM2 and APOE-expressing disease-associated microglia (DAM) in neurodegenerative lesions. Microglial senescence, mitochondrial failure, and chronic inflammation result from Nrf2/Keap1 redox pathway malfunction in ageing. Microglial interactions with astrocytes via IL-1α, TNF-α, and C1q result in neurotoxic or neuroprotective A2 astrocytes, demonstrating linked glial responses. Microglial inflammatory or reparative responses are influenced by epigenetic and metabolic reprogramming, such as regulation of PGC-1α, SIRT1, and glycolytic flux. Microglia are essential to neuroprotection and neurodegeneration. TREM2 agonists, NLRP3 inhibitors, and epigenetic modulators can treat chronic neuroinflammation and restore CNS homeostasis in neurodegenerative illnesses by targeting microglial signaling pathways.
Microglia are described as the immune cells of the brain, their immune properties have been extensively studied since first described, however, their neural functions have only been explored over the last decade. Microglia have an important role in maintaining homeostasis in the central nervous system by surveying their surroundings to detect pathogens or damage cells. While these are the classical functions described for microglia, more recently their neural functions have been defined; they are critical to the maturation of neurons during embryonic and postnatal development, phagocytic microglia remove excess synapses during development, a process called synaptic pruning, which is important to overall neural maturation. Furthermore, microglia can respond to neuronal activity and, together with astrocytes, can regulate neural activity, contributing to the equilibrium between excitation and inhibition through a feedback loop. Hypoxia at birth is a serious neurological condition that disrupts normal brain function resulting in seizures and epilepsy later in life. Evidence has shown that microglia may contribute to this hyperexcitability after neonatal hypoxia. This review will summarize the existing data on the role of microglia in the pathogenesis of neonatal hypoxia and the plausible mechanisms that contribute to the development of hyperexcitability after hypoxia in neonates.
Background Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy and is characterized by a pathological cascade of excitotoxicity that leads to neuroinflammation, progressive neuronal loss, and subsequent cognitive decline. Despite its prevalence, effective disease-modifying therapies remain lacking. Previous studies have demonstrated that the endocannabinoid system contributes to epileptic activity. In particular, inactivation of monoacylglycerol lipase (MAGL), the key rate-limiting enzyme responsible for the degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG), an endogenous lipid mediator with anti-inflammatory and neuroprotective properties, suppresses seizures and reduces neuroinflammation. However, the cellular and molecular mechanisms underlying these protective effects remain unclear. Methods To dissect the cellular mechanisms underlying MAGL-mediated neuroprotection, we employed a kainic acid (KA)-induced status epilepticus model in mice with global, astrocyte-specific (aKO), and neuron-specific (nKO) deletion of mgll. We combined single-nucleus RNA sequencing (snRNA-seq) to map the transcriptomic landscape of glial responses with pharmacological interventions to validate key signaling pathways, as well as behavioral assays to assess functional recovery. Results We demonstrated that astrocyte-specific, but not neuron-specific, mgll deletion was sufficient to attenuate seizure susceptibility and hippocampal neurodegeneration, thereby recapitulating the protective phenotype observed in global knockouts. Transcriptomic profiling revealed that astrocytic MAGL deficiency fundamentally reshaped the glial response to injury by preventing the transition to pro-inflammatory reactive astrocyte states and suppressing the activation of disease-associated microglia (DAM). Mechanistically, we identified a signaling pathway in which the neuroprotective effects of MAGL inhibition depend on cannabinoid receptor 1 (CB1) activation and are mediated by downstream peroxisome proliferator-activated receptor γ (PPAR-γ) signaling. Either genetic deletion of CB1 or pharmacological blockade of PPAR-γ abolished the protective effects. Furthermore, aKO mice exhibited reduced neuronal loss, preserved synaptic structural integrity and protection against post-seizure cognitive deficits. Conclusion These findings reveal astrocytic MAGL as a crucial regulatory node in the epileptic brain and demonstrated that enhancing 2-AG signaling in astrocytes orchestrates neuroprotection via CB1-PPAR-γ signaling pathways, thereby attenuating neuroinflammation, preserving synaptic function, and preventing the cognitive comorbidities associated with epilepsy.
In vertebrates, during an early wave of hematopoiesis in the yolk sac between embryonic day E7.0 and E9.0, cells of mesodermal leaflet addressed to macrophage lineage enter in developing central nervous system (CNS) and originate the developing native microglial cells. Depending on the species, microglial cells represent 5–20% of glial cells resident in adult brain. Here, we briefly discuss some canonical functions of the microglia, i.e., cytokine secretion and functional transition from M1 to M2 phenotype. In addition, we review studies on the non-canonical functions of microglia such as regulation of phagocytosis, synaptic pruning, and sculpting postnatal neural circuits. In this latter context the contribution of microglia to some neurodevelopmental disorders is now well established. Nasu-Hakola (NHD) disease is considered a primary microgliopathy with alterations of the DNAX activation protein 12 (DAP12)-Triggering receptor expressed on myeloid cells 2 (TREM-2) signaling and removal of macromolecules and apoptotic cells followed by secondary microglia activation. In Rett syndrome Mecp2-/- microglia shows a substantial impairment of phagocytic ability, although the role of microglia is not yet clear. In a mouse model of Tourette syndrome (TS), microglia abnormalities have also been described, and deficient microglia-mediated neuroprotection is obvious. Here we review the role of microglial cells in neurodevelopmental disorders without inflammation and on the complex role of microglia in developing CNS.
Microglia, the brain’s resident macrophages, help to regulate brain function by removing dying neurons, pruning non-functional synapses, and producing ligands that support neuronal survival1. Here we show that microglia are also critical modulators of neuronal activity and associated behavioural responses in mice. Microglia respond to neuronal activation by suppressing neuronal activity, and ablation of microglia amplifies and synchronizes the activity of neurons, leading to seizures. Suppression of neuronal activation by microglia occurs in a highly region-specific fashion and depends on the ability of microglia to sense and catabolize extracellular ATP, which is released upon neuronal activation by neurons and astrocytes. ATP triggers the recruitment of microglial protrusions and is converted by the microglial ATP/ADP hydrolysing ectoenzyme CD39 into AMP; AMP is then converted into adenosine by CD73, which is expressed on microglia as well as other brain cells. Microglial sensing of ATP, the ensuing microglia-dependent production of adenosine, and the adenosine-mediated suppression of neuronal responses via the adenosine receptor A1R are essential for the regulation of neuronal activity and animal behaviour. Our findings suggest that this microglia-driven negative feedback mechanism operates similarly to inhibitory neurons and is essential for protecting the brain from excessive activation in health and disease. Microglia, the brain’s immune cells, suppress neuronal activity in response to synaptic ATP release and alter behavioural responses in mice.
Microglia, the resident immune cells of the central nervous system, play multifaceted roles in both health and disease. During development, they regulate neurogenesis and refine neural circuits through synaptic pruning. In adulthood, microglia maintain homeostasis and dynamically respond to pathological insults, where they contribute to responding to neuroinflammatory challenges. This review summarizes microglial contributions to neurodevelopment and also outlines their function across various neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, highlighting both protective and detrimental effects. Finally, recent advances in microglial-targeted therapies and lifestyle-based interventions are highlighted, underscoring the translational potential of modulating microglial states. Elucidating the dual roles of microglia in development and disease could guide the design of therapeutic strategies aimed at enhancing neuroprotection while minimizing neurotoxicity.
Vascular dementia (VaD) is a leading cause of cognitive decline and arises from heterogeneous cerebrovascular pathologies, most commonly cerebral small vessel disease and chronic cerebral hypoperfusion. Microglia, the brain’s resident immune cells, exert a dual, stage-dependent influence during VaD progression, initially supporting neuroprotection through debris clearance and tissue repair, but later contributing to chronic neuroinflammation, synaptic loss, and white matter injury. Emerging evidence suggests that multiple molecular pathways, including purinergic receptors, Toll-like receptors and inflammasome cascades, complement-mediated synaptic pruning, and homeostatic and metabolic regulators, such as TREM2 (triggering receptor expressed on myeloid cells 2) and CSF1R (colony-stimulating factor 1 receptor), govern microglial functional transitions. Furthermore, post-transcriptional regulation by microRNAs (e.g., miR-30 family, miR-124, miR-146a, and miR-155) modulates these phenotypes, offering potential biomarkers and therapeutic targets. Understanding these interconnected molecular and epigenetic networks provides a framework for reprogramming microglia from pro-inflammatory to reparative states, thereby providing a mechanistic basis for precision interventions to preserve neurovascular integrity and mitigate cognitive impairment in VaD.
Abstract Drug-resistant epilepsy in pediatric patients is associated with neuroinflammation and neurodegeneration. Vitamin D 25-OH exerts neuroprotective effects, while glial cell line- derived neurotrophic factor (GDNF) and the proinflammatory cytokine interleukin-1β (IL-1β) are implicated in the mechanisms of neuroinflammation and epileptogenesis. The aim of this study was to investigate the relationship between vitamin D 25-OH, IL-1β, and GDNF levels with seizure severity and frequency in children with drug-resistant epilepsy. A cross-sectional study was conducted at Adam Malik Hospital, Medan, Indonesia, among children with drug-resistant epilepsy. Vitamin D 25-OH, IL-1β and GDNF levels were measured using enzyme-linked immunosorbent assay (ELISA). Epilepsy severity was assessed using the Hague Seizure Severity Scale (HASS), while seizure frequency was assessed using the Global Assessment of Severity of Epilepsy (GASE). The present study identified a significant correlation between GDNF levels and epilepsy severity, as measured by the HASS score (r=0.318; p=0.006). However, no significant correlation was observed between vitamin D 25-OH or IL-1β levels and epilepsy severity or seizure frequency (p>0.05). IL-1β levels correlated significantly with GDNF levels (r=0.525; p=0.001), but IL-1β did not directly correlate with seizure frequency or epilepsy severity. In conclusion, GDNF levels significantly correlated with epilepsy severity, suggesting that GDNF may serve as a potential biomarker for assessing epilepsy severity. However, further studies investigating the role of GDNF as a potential neurotrophic factor in the pathophysiology of epilepsy and its possible application as a therapeutic target are important.
The disruption of microglial homeostasis and cytokine release are critical for neuroinflammation post-injury and strongly implicated in retinal neurodegenerative diseases like glaucoma. This study examines microglial responses to chemical hypoxia induced by cobalt chloride (CoCl2) in BV-2 murine microglial cells, focusing on signaling pathways and proteomic alterations. We assessed the protective effects of monoclonal antibodies against TNFα and IL-1β. CoCl2 exposure led to decreased cell viability, reduced mitochondrial membrane potential, increased lactate dehydrogenase release, elevated reactive oxygen species generation, and activation of inflammatory pathways, including nitric oxide synthase (iNOS), STAT1, and NF-κB/NLRP3. These responses were significantly mitigated by treatment with anti-TNFα and anti-IL-1β, suggesting their dual role in reducing microglial damage and inhibiting inflammatory reactivity. Additionally, these treatments reduced apoptosis by modulating ATF4 and the p38 MAPK/caspase-3 pathways. Label-free quantitative mass spectrometry-based proteomics and Gene Ontology revealed that CoCl2 exposure led to the upregulation of proteins primarily involved in endoplasmic reticulum and catabolic processes, while downregulated proteins are associated with biosynthesis. Anti-TNFα and anti-IL-1β treatments partially restored the proteomic profile toward normalcy, with network analysis identifying heat shock protein family A member 8 (HSPA8) as a central mediator in recovery. These findings offer insights into the pathogenesis of hypoxic microglial impairment and suggest potential therapeutic targets.
An increasing number of observations have indicated that the activation of inflammatory processes is involved in the pathogenesis of epilepsy. As an effective adjunctive therapy for medically intractable seizures, vagus nerve stimulation (VNS) is thought to interact with the inflammatory process to play an antiepileptic role. In this study, we examined the levels of multiple cytokine in focal brain tissue and peripheral blood to determine whether the antiepileptic effect of chronic VNS is related to the expression of cytokines. We observed that the frequency and duration of seizures significantly decreased in epileptic rats after two weeks of chronic VNS treatment. Pathological staining showed that the number of neural cells in the hippocampus was higher in the Epi+VNS group than in the Epi group, indicating that chronic VNS had a significant neuroprotective effect on epileptic rats. After comparing the expression of 9 cytokines, we found that the levels of the proinflammatory cytokines IL-6, IL-1β and CXCL-1 in the hippocampus were significantly increased in the Epi group, while these cytokines were significantly decreased in the Epi+VNS group. Moreover, the level of the anti-inflammatory cytokine IL-13 was found to be reduced in Epi rats, while its levels were increased after VNS treatment. However, these changes in cytokine expression were not found in the hypothalamus or peripheral blood. These results suggest that the antiepileptic mechanism of VNS may work by inhibiting the activation of inflammatory processes in the epileptogenic focus.
Unprovoked recurrent seizures are a serious comorbidity affecting most patients who suffer from glioma, a primary brain tumor composed of malignant glial cells. Cellular mechanisms contributing to the development of recurrent spontaneous seizures include the release of the excitatory neurotransmitter glutamate from glioma into extracellular space. Under physiological conditions, astrocytes express two high affinity glutamate transporters, Glt-1 and Glast, which are responsible for the removal of excess extracellular glutamate. In the context of neurological disease or brain injury, astrocytes become reactive which can negatively affect neuronal function, causing hyperexcitability and/or death. Using electrophysiology, immunohistochemistry, fluorescent in situ hybridization, and Western blot analysis in different orthotopic xenograft and allograft models of human and mouse gliomas, we find that peritumoral astrocytes exhibit astrocyte scar formation characterized by proliferation, cellular hypertrophy, process elongation, and increased GFAP and pSTAT3. Overall, peritumoral reactive astrocytes show a significant reduction in glutamate and potassium uptake, as well as decreased glutamine synthetase activity. A subset of peritumoral astrocytes displayed a depolarized resting membrane potential, further contributing to reduced potassium and glutamate homeostasis. These changes may contribute to the propagation of peritumoral neuronal hyperexcitability and excitotoxic death.
Astrocytic dysfunction is increasingly recognised as an important contributor to epileptogenesis and seizure dynamics. Kir4.1 potassium channels expressed in astrocytes play a critical role in activity-dependent extracellular potassium buffering, and their loss may impair network stability and promote pathological hyperexcitability. In epilepsy, seizures can be accompanied by spreading depolarizations (SDs), propagating waves of neuronal and glial depolarization. While seizure-associated SDs have been proposed to terminate seizures and limit seizure spread, they have also been implicated in postictal dysfunction and sudden unexpected death in epilepsy (SUDEP), and their significance in chronic epilepsy remains unclear. Here, we tested whether focal loss of astrocytic Kir4.1 in the adult hippocampus is sufficient to disrupt potassium buffering, generate spontaneous seizures, and promote seizure-associated SDs. Using astrocyte-targeted viral vector Cre recombinase in adult Kir4.1-floxed mice, we induced focal hippocampal reduction of Kir4.1 expression. This impaired activity-dependent potassium buffering, producing enhanced stimulation-evoked extracellular potassium accumulation and larger DC shifts in hippocampal slices. Chronic wireless EEG recordings demonstrated that focal astrocytic Kir4.1 loss was sufficient to induce spontaneous recurrent seizures and interictal epileptiform activity. To investigate seizure-associated SDs, we combined optogenetic stimulation with graphene-based micro-transistor recordings capable of stable full-bandwidth DC electrophysiology in awake head-fixed mice. Focal hippocampal loss of astrocytic Kir4.1 markedly increased susceptibility to evoked seizures accompanied by SDs. We used chronic wireless DC-coupled video-telemetry recordings to continuously monitor seizure and SD dynamics in freely moving mice. SDs occurred frequently during generalized seizures and were first detected in cortical channels. Seizures accompanied by SDs exhibited greater spectral power, longer duration, and prolonged postictal depression compared with seizures alone. Behaviourally, seizures accompanied by SDs were linked to postictal impairment characterised by behavioural arrest and abnormal motor behaviours. These findings highlight the utility of graphene micro-transistor arrays and chronic DC-coupled telemetry for resolving infraslow (<0.1 Hz) epileptic dynamics that are largely inaccessible using conventional electrophysiological approaches. Ground-truth DC-coupled recordings enabled identification of AC-band electrographic signatures that segregated seizures with SDs from seizures alone, raising the possibility that SD-associated seizures may be retrospectively inferred from conventional AC-coupled epilepsy datasets. We demonstrate that focal astrocytic Kir4.1 loss in the adult brain impairs potassium buffering and is sufficient to drive spontaneous seizures, supporting astrocytic potassium dysregulation as a determinant of seizure and spreading depolarization susceptibility in epilepsy. Furthermore, seizure-associated SDs are strongly linked to increased postictal impairments, supporting the concept that SDs are major determinants of pathological postictal states.
: Ischemia-reperfusion (I/R) injury induces region-specific neuronal vulnerability within the hippocampus, with the cornu ammonis 1 (CA1) subfield particularly prone to delayed neuronal death. While intrinsic neuronal factors have been implicated, emerging evidence highlights the decisive contribution of astrocyte endfeet (AEF)— specialized perivascular structures that regulate ion and water homeostasis, glutamate clearance, and blood–brain barrier (BBB) stability. This review synthesizes structural and molecular alterations of AEF across the CA1–CA3 subfields following I/R and their correlation with neuronal fate. In CA1, AEF undergo early-onset swelling and detachment from the vascular basal lamina due to dysfunction of critical proteins such as aquaporin-4 (AQP4) and Kir4.1. These changes impair glutamate uptake, metabolic support, and potassium buffering, contributing to neuronal hyperexcitability and degeneration. In contrast, AEF in CA3 preserves polarity and functional coupling of AQP4 and Kir4.1, conferring regional resilience. At the signaling level, AEF disruption activates mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinase (JNK) pathways, promotes reactive oxygen species (ROS) accumulation, and induces inducible nitric oxide synthase (iNOS)-mediated inflammation, amplifying neurotoxicity. Furthermore, subfield-specific astrocytic transcriptional profiles modulate inflammatory responses and gliovascular interactions. By reframing AEF not as passive scaffolds but as active regulators of neuronal survival, this review provides novel insight into the astrocyte-dependent mechanisms of hippocampal vulnerability. Therapeutic strategies that preserve AEF structure and function may offer targeted protection against delayed neuronal death in ischemic brain injury.
Background Epilepsy initiation involves multifactorial etiologies, including genetic susceptibility, structural anomalies, and glial cell dysregulations, particularly in astrocytes. Despite advancements in understanding various factors, the mechanisms of astrocyte dysregulation in epilepsy, critical for neural homeostasis, remain elusive, requiring comprehensive evaluation of molecular pathways and cellular interactions for future targeted interventions. Methods A systematic search of PubMed, ScienceDirect, and the Cochrane databases up to January 1st 2024 identified relevant studies predominantly from experimental models, forming the basis for an in-depth analysis of astrocytic contributions to epileptic pathophysiology. The aims, subjects, epilepsy induction techniques, assessment methods, and findings of each studies were presented. Results A total of 24 clinical trials met the inclusion criteria and were included in the systematic review. Altered potassium buffering compromises extracellular potassium regulation, fostering hyperexcitability. Aquaporin dysfunction disrupts water homeostasis, aggravating seizure susceptibility. Disturbances in glutamatergic transmission, marked by changes in glutamate transporter function, contribute to excitotoxicity, fueling epileptogenesis. Intricacies in calcium signaling and disruptions in calcium-binding proteins tip intracellular calcium balance towards hyperexcitability. Dysfunctional GABA transporters compromise inhibitory neurotransmission, upsetting excitatory–inhibitory balance. Gap junction protein dysregulation disrupts astroglial networks, impacting neuronal synchronization in epileptogenic circuitry. Compromised BBB allows entry of epileptogenic factors, exacerbating the epileptogenic milieu. Conclusions Collectively, these astrocytic dysregulations unveil intricate contributors to epilepsy onset and progression.
The cerebellum, long studied as the principal center for motor coordination, is now recognized as a participant in epileptogenic network dynamics through the pathway running from the cerebellar cortex to the deep cerebellar nuclei and on to thalamic and cortical targets. Purkinje cells are the sole inhibitory output of the cerebellar cortex, and Bergmann glia, a radial astrocyte population apposed to Purkinje cell dendrites and parallel-fiber synapses, sustain the perisynaptic environment on which Purkinje cell firing depends through glutamate clearance by GLAST/EAAT1, potassium buffering by Kir4.1, and calcium-dependent signaling. In cortex and hippocampus, loss of the equivalent functions in protoplasmic astrocytes lowers seizure threshold and produces spontaneous seizures, but no comparable experiment has been performed in Bergmann glia. Molecular genetics has identified numerous epilepsy-associated genes, of which only SLC1A3, KCNJ10 and AQP4 have cell-type-resolved expression in Bergmann glia; the remainder act on cerebellar circuits through neurons. In human epilepsy, cerebellar atrophy with Purkinje cell loss and Bergmann gliosis tracks cumulative seizure burden and antiseizure medication exposure rather than a primary cerebellar lesion and is therefore best read as reactive. Reactive astrogliosis is nonetheless accompanied by reduced glutamate transport and potassium buffering in sclerotic hippocampus, and whether cerebellar reactive gliosis carries the same homeostatic cost has not been measured. This review sets out the circuit-level, genetic and neuropathological evidence bearing on that question and specifies the experiments that would answer it.
During neuronal activity, extracellular potassium concentration ([K+]out) becomes elevated and, if uncorrected, causes neuronal depolarization, hyperexcitability, and seizures. Clearance of K+ from the extracellular space, termed K+ spatial buffering, is considered to be an important function of astrocytes. Results from a number of studies suggest that maintenance of [K+]out by astrocytes is mediated by K+ uptake through the inward-rectifying Kir4.1 channels. To study the role of this channel in astrocyte physiology and neuronal excitability, we generated a conditional knock-out (cKO) of Kir4.1 directed to astrocytes via the human glial fibrillary acidic protein promoter gfa2. Kir4.1 cKO mice die prematurely and display severe ataxia and stress-induced seizures. Electrophysiological recordings revealed severe depolarization of both passive astrocytes and complex glia in Kir4.1 cKO hippocampal slices. Complex cell depolarization appears to be a direct consequence of Kir4.1 removal, whereas passive astrocyte depolarization seems to arise from an indirect developmental process. Furthermore, we observed a significant loss of complex glia, suggestive of a role for Kir4.1 in astrocyte development. Kir4.1 cKO passive astrocytes displayed a marked impairment of both K+ and glutamate uptake. Surprisingly, membrane and action potential properties of CA1 pyramidal neurons, as well as basal synaptic transmission in the CA1 stratum radiatum appeared unaffected, whereas spontaneous neuronal activity was reduced in the Kir4.1 cKO. However, high-frequency stimulation revealed greatly elevated posttetanic potentiation and short-term potentiation in Kir4.1 cKO hippocampus. Our findings implicate a role for glial Kir4.1 channel subunit in the modulation of synaptic strength.
The contribution of an impaired astrocytic K+ regulation system to epileptic neuronal hyperexcitability has been increasingly recognized in the last decade. A defective K+ regulation leads to an elevated extracellular K+ concentration ([K+]o). When [K+]o reaches peaks of 10–12 mM, it is strongly associated with seizure initiation during hypersynchronous neuronal activities. On the other hand, reactive astrocytes during a seizure attack restrict influx of K+ across the membrane both passively and actively. In addition to decreased K+ buffering, aberrant Ca2+ signaling and declined glutamate transport have also been observed in astrogliosis in epileptic specimens, precipitating an increased neuronal discharge and induction of seizures. This review aims to provide an overview of experimental findings that implicated astrocytic modulation of extracellular K+ in the mechanism of epileptogenesis.
Spatial Buffering During Slow and Paroxysmal Sleep Oscillations in Cortical Networks of Glial Cells In Vivo Amzica F, Massimini M, Manfridi A J Neurosci 2002;22:1042–1053 The ability of neuroglia to buffer local increases of extracellular K+ has been known from in vitro studies. This property may confer on these cells an active role in the modulation and spreading of cortical oscillatory activities. We addressed the question of the spatial buffering in vivo by performing single and double intraglial recordings, together with measures of the extracellular K+ and Ca2+ concentrations ([K+]out and [Ca2+]out) in the cerebral cortex of cats under ketamine and xylazine anesthesia during patterns of slow sleep oscillations and spike-wave seizures. In addition, we estimated the fluctuations of intraglial K+ concentrations ([K+]in). Measurements obtained during the slow oscillation indicated that glial cells phasically take up part of the extracellular K+ extruded by neurons during the depolarizing phase of the slow oscillation. During this condition, the redistribution of K+ appeared to be local. Large steady increases of [K+]out and phasic potassium accumulations were measured during spike-wave seizures. In this condition, [K+]in rose before [K+]out if the glial cells were located at some distance from the epileptic focus, suggesting faster K+ diffusion through the interglial syncytium. The simultaneously recorded [Ca2+]out dropped steadily during the seizures to levels incompatible with efficient synaptic transmission, but also displayed periodic oscillations, in phase with the intraseizure spike-wave complexes. In view of this fact, and considering the capability of K+ to modulate neuronal excitability both at the presynaptic and postsynaptic levels, we suggest that the K+ long-range spatial buffering operated by glia is a parallel synchronizing and/or spreading mechanism during paroxysmal oscillations. Calcium Oscillations in Neocortical Astrocytes under Epileptiform Conditions Tashiro A, Goldberg J, Yuste R J Neurobiol 2002;50:45–55 Morphological and functional alterations in astrocytic glia are often found in epileptic syndromes, although the exact role of astrocytes in epilepsy is poorly understood. During calcium imaging of epileptiform events in juvenile neocortical slices we previously discovered cells with spontaneous oscillations in their intracellular free calcium concentration ([Ca(2+)](i)). We have now characterized these oscillations using two in vitro models of epilepsy and find that they are produced by astrocytes. Astrocytic oscillations are widespread throughout the imaged territories, are remarkably regular and have long periods, averaging 100 s, which become shorter during development. Astrocytic oscillations are uncorrelated among themselves and with epileptiform events, are blocked by internal release antagonists and are stimulated by caffeine. Astrocytic calcium oscillations could mediate reactive astrogliosis, contribute to the pathogenesis of chronic epileptic syndromes, and be used as a diagnostic test for epileptic tissue.
No abstract available
Reactive astrocytes have been proposed to become incompetent bystanders in epilepsy as a result of cellular changes rendering them unable to perform important housekeeping functions. Indeed, successful surgical treatment of mesiotemporal lobe epilepsy hinges on the removal of the glial scar. New research now extends the role of astrocytes, suggesting that they may drive the disease process by impairing the inhibitory action of neuronal GABA receptors. Here we discuss studies that include hyperexcitability resulting from impaired supply of astrocytic glutamine for neuronal GABA synthesis, and epilepsy resulting from genetically induced astrogliosis or malignant transformation, both of which render the inhibitory neurotransmitter GABA excitatory. In these examples, glial cells alter the expression or function of neuronal proteins involved in excitability. Although epilepsy has traditionally been thought of as a disease caused by changes in neuronal properties exclusively, these new findings challenge us to consider the contribution of glial cells as drivers of epileptogenesis in acquired epilepsies.
No abstract available
Oxidative stress (OS) has a main role in the pathogenesis of central nervous system disorders. In this regard, epilepsy is a highly prevalent serious brain disease and its prevalence increases with age. Strikingly, about 50% of all epilepsy cases diagnosed in elderly patients (>65 years) are idiopathic. Metabolic changes, including the production of reactive oxygen species (ROS), are regarded to as possible mechanism involved in epileptogenesis. The neuronal glia plays a crucial role in epilepsy by controlling neuronal hyperexcitability. One of the key roles of glial cells is the spatial buffering of extracellular K+ ions that are released by excited neurons and transported through glial inwardly rectifying potassium (Kir) channels from extracellular regions of high K+ to those of low K+ to inhibit epileptogenesis. Among experimental OS‐related aging models, long‐term (24 hours) exposure to D‐Galactose (D‐Gal, 100 mM) is considered the most similar to natural aging. In the present study, we investigated the effect of D‐Gal‐induced aging on Kir channel activity in glioblastoma U87‐MG cells. Screening of all fifteen Kir isoforms revealed that the predominant transcript corresponds to Kir2.1, with minor contribution of Kir4.1. D‐Galactose had no obvious cytotoxicity, but strongly promoted OS, namely increased lipoperoxidation levels and decreased the membrane protein sulfhydryl group abundance. Interestingly, D‐Gal exposure was associated with a decrease of inwardly rectifying K+ currents sensitive to ML‐133, a specific inhibitor of Kir2.1 channels. Our findings reveal a novel Kir2.1 channel modulation that is likely to occur in OS. We suggest that inhibition of Kir2.1 channels in glia cells may alter extracellular K+ buffering and contribute to OS‐related neuronal hyperexcitability and epileptogenesis during aging.
No abstract available